\relax 
\catcode `"\active 
\select@language{german}
\@writefile{toc}{\select@language{german}}
\@writefile{lof}{\select@language{german}}
\@writefile{lot}{\select@language{german}}
\@writefile{toc}{\contentsline {chapter}{\numberline {1}Pharmakokinetik}{8}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {1.1}Definitionen}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakon}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Arzneistoff}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Arzneimittel}{8}}
\@writefile{toc}{\contentsline {section}{\numberline {1.2}Bezeichnung von Pharmaka}{8}}
\@writefile{toc}{\contentsline {section}{\numberline {1.3}Pharmakokinetik/Pharmakodynamik}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakodynamik}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Elimination}{8}}
\@writefile{toc}{\contentsline {section}{\numberline {1.4}Biotransformation / Metabolisierung}{8}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.1}{\ignorespaces Pharmakokinetik/Pharmakodynamik\relax }}{9}}
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{fig:Pharmakokinetik}{{1.1}{9}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.2}{\ignorespaces Biotransformation\relax }}{9}}
\newlabel{fig:Biotransformation}{{1.2}{9}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.1}Phase I: Funktionalisierungsreaktion}{9}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.2}Phase II: Konjugationsreaktion}{9}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.3}Bedeutung von Arzneimittelmetabolisierungsprozessen}{9}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.4}Superfamilie der humanen Cytochrom P450 Monooxygenasen}{10}}
\newlabel{sub:superfamilie_der_humanen_cytochrom_p450_monooxygenasen}{{1.4.4}{10}}
\@writefile{lot}{\contentsline {table}{\numberline {1.1}{\ignorespaces F\IeC {\"u}r den Fremdstoffmetabolismus wichtige Vertreter aus der Superfamilie der humanen Cytochrom P450 Monooxygenasen (CYP)\relax }}{10}}
\newlabel{tab:CYP450}{{1.1}{10}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.3}{\ignorespaces CYP-Beispiele\relax }}{10}}
\newlabel{fig:cyp-beispiele}{{1.3}{10}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.5}Induktion von Cytochrom P450 Monooxygenasen}{10}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.6}Arzneimittelinteraktionen durch Enzymhemmung und -induktion}{10}}
\@writefile{toc}{\contentsline {subsubsection}{Enzyminduktion (Beispiele)}{10}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.4}{\ignorespaces Induktion von Cytochrom P450 Monooxygenasen\relax }}{11}}
\newlabel{fig:cytochrom2}{{1.4}{11}}
\@writefile{lot}{\contentsline {table}{\numberline {1.2}{\ignorespaces Induktion von Cytochrom P450 Monooxygenasen\relax }}{11}}
\newlabel{tab:cypinduktion}{{1.2}{11}}
\@writefile{toc}{\contentsline {subsubsection}{Enzymhemmung (Beispiele)}{11}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.7}Phase II Reaktionen}{11}}
\@writefile{toc}{\contentsline {subsubsection}{Glucuronosyltransferasen}{11}}
\@writefile{toc}{\contentsline {subsubsection}{Glutathion-S-Transferase (GST)}{11}}
\@writefile{toc}{\contentsline {subsubsection}{N-Acetyltransferase (NAT) }{11}}
\@writefile{toc}{\contentsline {subsubsection}{Sulfotransferase (SULT)}{12}}
\@writefile{toc}{\contentsline {subsubsection}{Methyltransferase}{12}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.8}Bildung aktiver oder toxischer Metabolite (Beispiele)}{12}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.5}{\ignorespaces Bildung aktiver oder toxischer Metabolite (Beispiele)\relax }}{12}}
\newlabel{fig:Metabolite}{{1.5}{12}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.9}First-Pass-Effekt}{12}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.6}{\ignorespaces First-Pass-Effekt\relax }}{12}}
\newlabel{fig:FirstPass}{{1.6}{12}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4.10}Pharmakogenetik / Genetisch bedingte Unterschiede in der Metabolisierung von Pharmaka (Beispiele)}{12}}
\@writefile{toc}{\contentsline {subsubsection}{Phase I}{12}}
\@writefile{toc}{\contentsline {subsubsection}{Phase II}{12}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.7}{\ignorespaces Ethanol Biotransformation\relax }}{13}}
\newlabel{fig:EthanolBiotransformation}{{1.7}{13}}
\@writefile{toc}{\contentsline {section}{\numberline {1.5}Ausscheidung}{13}}
\@writefile{toc}{\contentsline {subsubsection}{renal}{13}}
\@writefile{toc}{\contentsline {subsubsection}{bil\IeC {\"a}r/intestinal}{13}}
\@writefile{toc}{\contentsline {subsubsection}{pulmonal}{13}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.5.1}Elimination von Pharmaka}{13}}
\@writefile{toc}{\contentsline {section}{\numberline {1.6}Pharmakokinetische Parameter}{13}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.6.1}Bioververf\IeC {\"u}gbarkeit}{13}}
\@writefile{toc}{\contentsline {subsubsection}{Bei oraler gabe abh\IeC {\"a}ngig von}{13}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.6.2}\IeC {\quotedblbase }area under the curve\IeC {\textquotedblright } (AUC)}{13}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.8}{\ignorespaces Elimination\relax }}{14}}
\newlabel{fig:Elimination}{{1.8}{14}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.9}{\ignorespaces Bioverf\IeC {\"u}gbarkeit\relax }}{14}}
\newlabel{fig:Bioverfuegbarkeit}{{1.9}{14}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.6.3}Verteilungsvolumen}{14}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.6.4}Clearance}{14}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.6.5}Plasmahalbwertszeit $t_{\frac  {1}{2}}$}{14}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.10}{\ignorespaces Clearance\relax }}{15}}
\newlabel{fig:Clearance}{{1.10}{15}}
\newlabel{fig:transmebrandomaene}{{1.11a}{15}}
\newlabel{sub@fig:transmebrandomaene}{{a}{15}}
\newlabel{fig:kinetik1}{{1.11b}{15}}
\newlabel{sub@fig:kinetik1}{{b}{15}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.11}{\ignorespaces Kinetik 0. und 1. Ordung\relax }}{15}}
\newlabel{fig:struktur_na_kanal}{{1.11}{15}}
\@writefile{toc}{\contentsline {subsubsection}{Kinetik nach wiederholter Gabe}{15}}
\@writefile{toc}{\contentsline {subsubsection}{Kumulation}{15}}
\@writefile{toc}{\contentsline {chapter}{\numberline {2}Pharmakodynamik}{16}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {2.1}Angriffsorte von Pharmaka}{16}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1.1}Fremdorganismus / Mikroorganismus}{16}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1.2}Menschlicher / tierischer Organismus (Makroorganismus)}{16}}
\@writefile{toc}{\contentsline {subsubsection}{Extrazellul\IeC {\"a}r}{16}}
\@writefile{toc}{\contentsline {subsubsection}{Zellul\IeC {\"a}r}{16}}
\@writefile{toc}{\contentsline {section}{\numberline {2.2}Kan\IeC {\"a}le: Definiton und Funktion}{16}}
\@writefile{toc}{\contentsline {subsubsection}{Na$^+$-Kan\IeC {\"a}le}{16}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.1}{\ignorespaces Kan\IeC {\"a}le der Zellmembran\relax }}{17}}
\newlabel{fig:Kanaele}{{2.1}{17}}
\newlabel{fig:transmembranna}{{2.2a}{17}}
\newlabel{sub@fig:transmembranna}{{a}{17}}
\newlabel{fig:transmebrandomaene}{{2.2b}{17}}
\newlabel{sub@fig:transmebrandomaene}{{b}{17}}
\newlabel{fig:aufsicht}{{2.2c}{17}}
\newlabel{sub@fig:aufsicht}{{c}{17}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.2}{\ignorespaces Struktur des Na$^+$-Kanals\relax }}{17}}
\newlabel{fig:struktur_na_kanal}{{2.2}{17}}
\@writefile{toc}{\contentsline {subsubsection}{Ca$^{2+}$-Kan\IeC {\"a}le}{17}}
\newlabel{fig:transmembranna}{{2.3a}{17}}
\newlabel{sub@fig:transmembranna}{{a}{17}}
\newlabel{fig:transmebrandomaene}{{2.3b}{17}}
\newlabel{sub@fig:transmebrandomaene}{{b}{17}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.3}{\ignorespaces Struktur des Ca$^{2+}$-Kanals\relax }}{17}}
\newlabel{fig:struktur_ca_kanal}{{2.3}{17}}
\@writefile{toc}{\contentsline {subsubsection}{K$^+$-Kan\IeC {\"a}le}{17}}
\@writefile{toc}{\contentsline {section}{\numberline {2.3}Transporter: Definition und Funktion}{17}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.3.1}Carrier}{17}}
\newlabel{fig:transmembranna}{{2.4a}{18}}
\newlabel{sub@fig:transmembranna}{{a}{18}}
\newlabel{fig:transmebrandomaene}{{2.4b}{18}}
\newlabel{sub@fig:transmebrandomaene}{{b}{18}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.4}{\ignorespaces Struktur des K$^+$-Kanals\relax }}{18}}
\newlabel{fig:struktur_k_kanal}{{2.4}{18}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.5}{\ignorespaces Carrier und Pumpensysteme\relax }}{18}}
\newlabel{fig:carrierpumpen}{{2.5}{18}}
\@writefile{toc}{\contentsline {subsubsection}{Na$^+$/Neurotransmitter-Kotransporter}{18}}
\@writefile{toc}{\contentsline {subsubsection}{Kation/Cl$^-$-Kotransporter}{18}}
\newlabel{fig:neurotransmitterkotransporter}{{2.6a}{18}}
\newlabel{sub@fig:neurotransmitterkotransporter}{{a}{18}}
\newlabel{fig:kationencarrier}{{2.6b}{18}}
\newlabel{sub@fig:kationencarrier}{{b}{18}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.6}{\ignorespaces Carrier - Beispiele\relax }}{18}}
\newlabel{fig:carrierbsp}{{2.6}{18}}
\@writefile{toc}{\contentsline {subsubsection}{Pumpen}{18}}
\@writefile{toc}{\contentsline {paragraph}{Ionenpumpen}{18}}
\gdef \LT@i {\LT@entry 
    {1}{127.83357pt}\LT@entry 
    {1}{103.04872pt}\LT@entry 
    {1}{118.41693pt}\LT@entry 
    {1}{125.81102pt}}
\gdef \LT@ii {\LT@entry 
    {1}{137.13911pt}\LT@entry 
    {1}{107.08356pt}}
\@writefile{toc}{\contentsline {paragraph}{ABC-Transporter}{19}}
\@writefile{toc}{\contentsline {section}{\numberline {2.4}Enzyme}{19}}
\@writefile{lot}{\contentsline {table}{\numberline {2.2}{\ignorespaces \IeC {\"U}bersicht: pharmakologisch relevante Enzyme\relax }}{19}}
\newlabel{tab:relevante_enzyme}{{2.2}{19}}
\@writefile{toc}{\contentsline {section}{\numberline {2.5}Rezeptor: Definition und Funktion}{19}}
\gdef \LT@iii {\LT@entry 
    {1}{97.35826pt}\LT@entry 
    {1}{97.35826pt}\LT@entry 
    {2}{88.17441pt}\LT@entry 
    {1}{182.71652pt}}
\@writefile{lot}{\contentsline {table}{\numberline {2.4}{\ignorespaces \IeC {\"U}bersicht: pharmakologisch relevante Enzyme\relax }}{20}}
\newlabel{tab:relevante_enzyme}{{2.4}{20}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.7}{\ignorespaces G-Protein\relax }}{20}}
\newlabel{fig:gprotein}{{2.7}{20}}
\@writefile{toc}{\contentsline {section}{\numberline {2.6}Rezeptortypen}{20}}
\@writefile{toc}{\contentsline {section}{\numberline {2.7}G-Protein-gekoppelte Rezeptoren (GPCR)}{20}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.7.1}Aktivierungs-/Inaktivierungs-Zyklus}{20}}
\@writefile{toc}{\contentsline {section}{\numberline {2.8}G-Protein vermittelte Signalwege (ubiquit\IeC {\"a}r)}{20}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.8.1}G$_s$-gekoppelte Rezeptoren}{20}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiele}{20}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.8.2}G$_{i/o}$-gekoppelte Rezeptoren}{20}}
\gdef \LT@iv {\LT@entry 
    {1}{59.0001pt}\LT@entry 
    {1}{65.88899pt}\LT@entry 
    {1}{92.84744pt}\LT@entry 
    {1}{125.81102pt}}
\gdef \LT@v {\LT@entry 
    {1}{100.72243pt}\LT@entry 
    {1}{107.97235pt}\LT@entry 
    {1}{281.38951pt}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.8}{\ignorespaces GPCR-Zyklus\relax }}{21}}
\newlabel{fig:gpcrzyklus}{{2.8}{21}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiele}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.9}Liganden-gesteuerte Ionenkan\IeC {\"a}le}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.10}Liganden-regulierte Enzyme}{21}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.10.1}Rezeptoren mit Tyrosinkinase-Aktivit\IeC {\"a}t (Beispiel: Insulin-Rezeptor)}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.11}nukle\IeC {\"a}re Rezeptoren}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.12}Pharmakon-Rezeptor-Interaktion}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.13}Wirkungsausl\IeC {\"o}sung}{21}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.13.1}Intrinsische Aktivit\IeC {\"a}t (Wirksamkeit, \IeC {\quotedblbase }efficacy\IeC {\textquotedblleft })}{21}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.13.2}Konzentrations-Wirkungs-Beziehung:}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.14}Wirksamkeit/Potenz}{21}}
\@writefile{toc}{\contentsline {subsubsection}{Potenz}{21}}
\@writefile{toc}{\contentsline {subsubsection}{Wirksamkeit}{21}}
\@writefile{lot}{\contentsline {table}{\numberline {2.6}{\ignorespaces \IeC {\"U}bersicht: pharmakologisch relevante Enzyme\relax }}{22}}
\newlabel{tab:relevante_enzyme}{{2.6}{22}}
\newlabel{fig:ligand1}{{2.9a}{23}}
\newlabel{sub@fig:ligand1}{{a}{23}}
\newlabel{fig:ligand2}{{2.9b}{23}}
\newlabel{sub@fig:ligand2}{{b}{23}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.9}{\ignorespaces Liganden-regulierte Enzyme\relax }}{23}}
\newlabel{fig:liganden_enzyme}{{2.9}{23}}
\@writefile{lot}{\contentsline {table}{\numberline {2.8}{\ignorespaces Wichtige Rezeptortypen\relax }}{23}}
\newlabel{tab:rezeptortypen}{{2.8}{23}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.10}{\ignorespaces Beispiel: Insulinrezeptor\relax }}{24}}
\newlabel{fig:insulinrezeptor}{{2.10}{24}}
\@writefile{lot}{\contentsline {table}{\numberline {2.10}{\ignorespaces Relevante Liganden und ihre nukle\IeC {\"a}ren Rezeptoren\relax }}{24}}
\newlabel{tab:nukleaererezeptoren}{{2.10}{24}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.11}{\ignorespaces Pharmakon-Rezeptor-Interaktion: \textit  {k$_1$}: Geschwindigkeitskonstante der Assoziation; \textit  {k$_2$}: eschwindigkeitskonstante der Dissoziation im \IeC {\"A}quilibrium gilt gem\IeC {\"a}\IeC {\ss } Massenwirkungsgesetz: \textit  {K$_D$}: \IeC {\"A}quilibrium-Dissoziations-Konstante Ma\IeC {\ss } f\IeC {\"u}r die Affinit\IeC {\"a}t K$_D$ der meisten physiologischen Rezeptoren im Bereich von: 10$^{-9}$ - 10$^{-6}$ M\relax }}{24}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.12}{\ignorespaces Wirkungsausl\IeC {\"o}sung: Der Effekt ist proportional der Rezeptor-Besetzung\relax }}{24}}
\newlabel{fig:ligand1}{{2.13a}{25}}
\newlabel{sub@fig:ligand1}{{a}{25}}
\newlabel{fig:ligand2}{{2.13b}{25}}
\newlabel{sub@fig:ligand2}{{b}{25}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.13}{\ignorespaces Instrinsische Aktivit\IeC {\"a}t, EC$_50$, Potenz\relax }}{25}}
\newlabel{fig:liganden_enzyme}{{2.13}{25}}
\newlabel{fig:agonimus}{{2.14a}{25}}
\newlabel{sub@fig:agonimus}{{a}{25}}
\newlabel{fig:rezeptorzustande}{{2.14b}{25}}
\newlabel{sub@fig:rezeptorzustande}{{b}{25}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.14}{\ignorespaces Agonismus\relax }}{25}}
\newlabel{fig:agonimusundpotenz}{{2.14}{25}}
\@writefile{toc}{\contentsline {section}{\numberline {2.15}Agonismus}{25}}
\@writefile{toc}{\contentsline {subsubsection}{Agonist}{25}}
\@writefile{toc}{\contentsline {section}{\numberline {2.16}Antagonismus}{25}}
\@writefile{toc}{\contentsline {subsubsection}{Antagonist}{25}}
\@writefile{toc}{\contentsline {subsubsection}{kompetitiver Antagonismus}{25}}
\@writefile{toc}{\contentsline {subsubsection}{nichtkompetitiver Antagonismus}{25}}
\newlabel{fig:agonimus}{{2.15a}{26}}
\newlabel{sub@fig:agonimus}{{a}{26}}
\newlabel{fig:rezeptorzustande}{{2.15b}{26}}
\newlabel{sub@fig:rezeptorzustande}{{b}{26}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.15}{\ignorespaces Antagonismus\relax }}{26}}
\newlabel{fig:antagonimus}{{2.15}{26}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.16}{\ignorespaces Pharmakolokinetische Toleranz\relax }}{26}}
\newlabel{fig:pharmakokinetischetoleranz}{{2.16}{26}}
\@writefile{toc}{\contentsline {section}{\numberline {2.17}Toleranzph\IeC {\"a}nomene}{26}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.17.1}Toleranz}{26}}
\@writefile{toc}{\contentsline {subsubsection}{pharmakokinetische Toleranz}{26}}
\@writefile{toc}{\contentsline {subsubsection}{pharmakodynamische Toleranz}{26}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.17.2}Tachyphylaxie}{26}}
\@writefile{toc}{\contentsline {section}{\numberline {2.18}Unerw\IeC {\"u}nschte Wirkungen von Pharmaka}{26}}
\@writefile{toc}{\contentsline {subsubsection}{Hauptwirkung}{26}}
\@writefile{toc}{\contentsline {subsubsection}{Nebenwirkung}{26}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkung}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.1}H\IeC {\"a}ufigkeit unerw\IeC {\"u}nschter Arzneimittelwirkungen}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.2}Unerw\IeC {\"u}nschte Wirkungen im Rahmen des pharmakodynamischen Wirkprofils}{27}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.17}{\ignorespaces Therapeutische Breite\relax }}{27}}
\newlabel{fig: therbreite}{{2.17}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.3}Ursachen dosisabh\IeC {\"a}ngiger unerw\IeC {\"u}nschter Arzneimittelwirkungen}{27}}
\@writefile{toc}{\contentsline {subsubsection}{Absolute \IeC {\"U}berdosierung}{27}}
\@writefile{toc}{\contentsline {subsubsection}{Relative \IeC {\"U}berdosierung}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.4}Arzneimittel-unabh\IeC {\"a}ngige Faktoren, die zu einer relativen \IeC {\"U}berdosierung f\IeC {\"u}hren}{27}}
\gdef \LT@vi {\LT@entry 
    {1}{125.81102pt}\LT@entry 
    {2}{165.30592pt}\LT@entry 
    {2}{199.36153pt}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.5}Unerw\IeC {\"u}nschte Wirkungen durch Arzneimittelinteraktionen}{28}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiele}{28}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.6}Unerw.Wirkungen au\IeC {\ss }erhalb des pharmakodynam. Wirkprofils}{28}}
\@writefile{toc}{\contentsline {subsubsection}{Arzneimittelallergie}{28}}
\@writefile{toc}{\contentsline {subsubsection}{Pseudoallergische Reaktion}{28}}
\@writefile{lot}{\contentsline {table}{\numberline {2.12}{\ignorespaces Beispiele: unerw\IeC {\"u}schte Arzneimittelinteraktionen\relax }}{29}}
\newlabel{tab:arzneimittelinteraktionen}{{2.12}{29}}
\gdef \LT@vii {\LT@entry 
    {1}{79.0557pt}\LT@entry 
    {1}{106.86134pt}\LT@entry 
    {1}{154.94475pt}}
\@writefile{toc}{\contentsline {chapter}{\numberline {3}Cholinerges System}{30}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {3.1}cholinerge und adrenerge \IeC {\"U}bertragung im peripheren efferenten Nervensystem}{30}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.1}{\ignorespaces Cholinerges System im Vergleich\relax }}{30}}
\newlabel{fig:cholinergessystem}{{3.1}{30}}
\@writefile{lot}{\contentsline {table}{\numberline {3.2}{\ignorespaces Eigenschaften des somatomotorischen und autonomen Systems\relax }}{31}}
\newlabel{tab:somatomotorischautonom}{{3.2}{31}}
\newlabel{fig:acetylcholin}{{3.2a}{31}}
\newlabel{sub@fig:acetylcholin}{{a}{31}}
\newlabel{fig:achsynapse}{{3.2b}{31}}
\newlabel{sub@fig:achsynapse}{{b}{31}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.2}{\ignorespaces Acetylcholin-System\relax }}{31}}
\newlabel{fig:achsystem}{{3.2}{31}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1.1}Eigenschaften des somatomotor. und autonomen Systems}{31}}
\@writefile{toc}{\contentsline {section}{\numberline {3.2}Acetylcholin}{31}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2.1}Cholinerge Synapse}{31}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2.2}Acetylcholinesterase}{31}}
\@writefile{toc}{\contentsline {subsubsection}{motorische Endplatte}{31}}
\@writefile{toc}{\contentsline {subsubsection}{ZNS}{31}}
\@writefile{toc}{\contentsline {subsubsection}{sezernierte Form}{31}}
\gdef \LT@viii {\LT@entry 
    {1}{80.55568pt}\LT@entry 
    {1}{202.72266pt}\LT@entry 
    {1}{234.94504pt}\LT@entry 
    {1}{77.00015pt}}
\newlabel{fig:endplatte}{{3.3a}{32}}
\newlabel{sub@fig:endplatte}{{a}{32}}
\newlabel{fig:zns}{{3.3b}{32}}
\newlabel{sub@fig:zns}{{b}{32}}
\newlabel{fig:sezernierte_form}{{3.3c}{32}}
\newlabel{sub@fig:sezernierte_form}{{c}{32}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.3}{\ignorespaces Subtypen der Acetylcholinesterase\relax }}{32}}
\newlabel{fig:achesterase}{{3.3}{32}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.4}{\ignorespaces muskarinischer G-Proteinrezeptor\relax }}{32}}
\newlabel{fig:mgpr}{{3.4}{32}}
\@writefile{toc}{\contentsline {section}{\numberline {3.3}Pharmakologische Beeinflussung cholinerger Systeme}{32}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.1}Cholinerge Rezeptoren}{32}}
\@writefile{toc}{\contentsline {subsubsection}{muskarinisch}{32}}
\@writefile{toc}{\contentsline {subsubsection}{nikotinisch}{32}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.2}Agonisten / Antagonisten des nikotinischen Ach-Rezeptor}{32}}
\@writefile{toc}{\contentsline {subsubsection}{Nikotin}{32}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{32}}
\@writefile{lot}{\contentsline {table}{\numberline {3.4}{\ignorespaces Cholinerge Rezeptoren\relax }}{32}}
\newlabel{tab:cholrezeptoren}{{3.4}{32}}
\gdef \LT@ix {\LT@entry 
    {1}{92.19463pt}\LT@entry 
    {1}{163.88916pt}\LT@entry 
    {1}{60.33345pt}\LT@entry 
    {1}{63.41681pt}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.5}{\ignorespaces Nikotinischer Acetylcholinrezeptor\relax }}{33}}
\newlabel{fig:achrezeptor}{{3.5}{33}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakodynamik}{33}}
\@writefile{toc}{\contentsline {subsubsection}{Cytisin / Vareniclin}{33}}
\@writefile{toc}{\contentsline {subsubsection}{Muskelrelaxantien}{33}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.6}{\ignorespaces Motorische Endplatte\relax }}{33}}
\newlabel{fig:motorischeendplatte}{{3.6}{33}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{33}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{33}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{33}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.3}nicht-depolarisierende Muskelrelaxantien}{33}}
\@writefile{lot}{\contentsline {table}{\numberline {3.6}{\ignorespaces Nicht-depolarisierende Muskelrelaxantien\relax }}{33}}
\newlabel{tab:nukleaererezeptoren}{{3.6}{33}}
\@writefile{toc}{\contentsline {paragraph}{Elimination}{33}}
\@writefile{toc}{\contentsline {paragraph}{Antidot}{33}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.4}depolarisiernde Muskelrelaxantien}{34}}
\@writefile{toc}{\contentsline {subsubsection}{Suxamethonium, Succinylcholin}{34}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{34}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{34}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{34}}
\@writefile{toc}{\contentsline {section}{\numberline {3.4}Agonisten / Antagonisten muskarinischer Rezeptoren antimuskarinerge Substanzen / Parasympatholytika}{34}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4.1}Belladonna-Alkaloide}{34}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{34}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4.2}M3-selektiv}{34}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4.3}quartern\IeC {\"a}re Derivate}{34}}
\gdef \LT@x {\LT@entry 
    {1}{65.88899pt}\LT@entry 
    {1}{54.30566pt}\LT@entry 
    {1}{45.33344pt}\LT@entry 
    {1}{135.72246pt}}
\@writefile{lot}{\contentsline {table}{\numberline {3.8}{\ignorespaces Relevante Liganden und ihre nukle\IeC {\"a}ren Rezeptoren\relax }}{35}}
\newlabel{tab:nukleaererezeptoren}{{3.8}{35}}
\@writefile{toc}{\contentsline {paragraph}{Hauptindikationen f\IeC {\"u}r Parasympatholytika}{35}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen (je nach erw\IeC {\"u}nschter Wirkung)}{35}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{35}}
\@writefile{toc}{\contentsline {section}{\numberline {3.5}muskarinerge Agonisten / direkte Parasympathomimetika}{35}}
\@writefile{toc}{\contentsline {paragraph}{Hauptindikation f\IeC {\"u}r direkte Parasympathomimetika}{35}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkung}{35}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{35}}
\@writefile{toc}{\contentsline {section}{\numberline {3.6}Cholinesterase-Hemmer/indirekte Parasympathomimetika}{35}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.1}Hydrolyse von Ach durch AchE:}{35}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.2}Wirkung von AchE-Hemmern:}{35}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.7}{\ignorespaces Zyklus der Acetylcholinesterase\relax }}{36}}
\newlabel{fig:achesterasezyklus}{{3.7}{36}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.8}{\ignorespaces Hemmung der Acetylcholinesterase\relax }}{36}}
\newlabel{fig:achesterasehemmung}{{3.8}{36}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.3}reversible AchE-Hemmer}{36}}
\@writefile{toc}{\contentsline {subsubsection}{nicht-kovalent}{36}}
\newlabel{ssub:nicht_kovalent}{{3.6.3}{36}}
\@writefile{toc}{\contentsline {subsubsection}{kovalent (carbamylierend)}{36}}
\newlabel{ssub:kovalent_carbamylierend_}{{3.6.3}{36}}
\@writefile{toc}{\contentsline {paragraph}{Hauptindikationen f\IeC {\"u}r ind. Parasympathomimetika}{36}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.4}irreversible AchE-Hemmer}{37}}
\@writefile{toc}{\contentsline {subsubsection}{Kampfstoffe}{37}}
\newlabel{ssub:kampfstoffe}{{3.6.4}{37}}
\@writefile{toc}{\contentsline {chapter}{\numberline {4}Adrenerges System}{38}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {subsubsection}{Katecholaminsynthese}{38}}
\@writefile{toc}{\contentsline {subsubsection}{Abbau von Katecholaminen}{38}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.0.5}adrenerge Varikosit\IeC {\"a}t}{38}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.0.6}Hemmer der NA-Freisetzung}{38}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.0.7}indirekte Sympathomimetika}{38}}
\@writefile{toc}{\contentsline {paragraph}{Effekt von Amphetamin auf die Noradrenalin (NA)-Freisetzung:}{39}}
\@writefile{toc}{\contentsline {section}{\numberline {4.1}adrenerge Rezeptoren}{39}}
\@writefile{lot}{\contentsline {table}{\numberline {4.1}{\ignorespaces \relax }}{39}}
\newlabel{}{{4.1}{39}}
\@writefile{toc}{\contentsline {section}{\numberline {4.2}$\beta _2$-Adrenozeptor-Agonisten / $\beta _2$-Sympathomimetika }{39}}
\@writefile{toc}{\contentsline {paragraph}{Gabe}{39}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{39}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{39}}
\@writefile{toc}{\contentsline {section}{\numberline {4.3}$\alpha $-Adrenozeptor-Agonisten}{39}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{40}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{40}}
\@writefile{toc}{\contentsline {section}{\numberline {4.4}$\alpha _2$-Adrenozeptor-Agonisten}{40}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{40}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{40}}
\@writefile{toc}{\contentsline {section}{\numberline {4.5}$\alpha _1$-Adrenozeptor-Antagonisten}{40}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{40}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{40}}
\@writefile{toc}{\contentsline {section}{\numberline {4.6}\IeC {\textbullet }}{40}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.1}Wirkprofil}{40}}
\@writefile{toc}{\contentsline {subsubsection}{$\beta _1$-Selektivit\IeC {\"a}t (\IeC {\quotedblbase }Kardioselektivit\IeC {\"a}t\IeC {\textquotedblleft })}{40}}
\@writefile{lot}{\contentsline {table}{\numberline {4.2}{\ignorespaces \relax }}{41}}
\newlabel{}{{4.2}{41}}
\@writefile{toc}{\contentsline {subsubsection}{partielle agonistische Aktivit\IeC {\"a}t (PAA)}{41}}
\@writefile{toc}{\contentsline {subsubsection}{\IeC {\quotedblbase }membranstabilisierende Wirkung\IeC {\textquotedblleft }}{41}}
\@writefile{toc}{\contentsline {subsubsection}{vasodilatierende Wirkung}{41}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.2}Pharmakokinetik}{41}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.3}Kontraindikationen}{41}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.4}Wechselwirkungen}{41}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.5}Indikation}{42}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.6}unerw\IeC {\"u}nschte Wirkungen}{42}}
\@writefile{toc}{\contentsline {section}{\numberline {4.7}Relative Rezeptorselektivit\IeC {\"a}t von Adrenozeptor-Agonisten und -Antagonisten}{42}}
\@writefile{toc}{\contentsline {chapter}{\numberline {5}RAAS/ Diuretika}{43}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {5.1}Renin-Angiotensin-System}{43}}
\@writefile{toc}{\contentsline {section}{\numberline {5.2}Renin-Inhibitoren}{43}}
\@writefile{toc}{\contentsline {subsubsection}{Aliskiren}{43}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{43}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{43}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{43}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{43}}
\@writefile{toc}{\contentsline {section}{\numberline {5.3}ACE-Hemmer}{43}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{43}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{43}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{44}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{44}}
\@writefile{toc}{\contentsline {paragraph}{Wechselwirkungen}{44}}
\@writefile{toc}{\contentsline {section}{\numberline {5.4}$AT_1$-Rezeptor-Antagonisten}{44}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{44}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{44}}
\@writefile{toc}{\contentsline {section}{\numberline {5.5}Klassen von Diuretika}{44}}
\@writefile{toc}{\contentsline {subsection}{\numberline {5.5.1}Tubuloglomerul\IeC {\"a}re Feedback-Mechanismen}{44}}
\@writefile{toc}{\contentsline {paragraph}{Regulation der GFR des Einzelnephrons}{44}}
\@writefile{toc}{\contentsline {paragraph}{Regulation der Reninfreisetzung \IeC {\"u}ber MD}{44}}
\@writefile{toc}{\contentsline {section}{\numberline {5.6}Schleifendiuretika}{44}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{45}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{45}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{45}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{45}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{45}}
\@writefile{toc}{\contentsline {section}{\numberline {5.7}Thiazide}{45}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{45}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{46}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{46}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{46}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{46}}
\@writefile{toc}{\contentsline {section}{\numberline {5.8}K$^+$-sparende Diuretika}{46}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{46}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{46}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{46}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{46}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{47}}
\@writefile{toc}{\contentsline {paragraph}{Wechselwirkungen}{47}}
\@writefile{toc}{\contentsline {section}{\numberline {5.9}Mineralokortikoid-Rezeptor-Antagonisten}{47}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{47}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{47}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{47}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{47}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{47}}
\@writefile{toc}{\contentsline {paragraph}{Kontrainkdikationen}{47}}
\@writefile{toc}{\contentsline {section}{\numberline {5.10}Arterielle Hypertonie}{47}}
\@writefile{toc}{\contentsline {section}{\numberline {5.11}Therapie der Hypertonie}{48}}
\@writefile{toc}{\contentsline {subsubsection}{Ziel}{48}}
\@writefile{toc}{\contentsline {subsubsection}{nicht-medikament\IeC {\"o}s}{48}}
\@writefile{toc}{\contentsline {subsubsection}{medikament\IeC {\"o}s}{48}}
\@writefile{toc}{\contentsline {paragraph}{RR hochnormal}{48}}
\@writefile{toc}{\contentsline {paragraph}{Stadium 1}{48}}
\@writefile{toc}{\contentsline {paragraph}{Stadium 2 und 3}{48}}
\@writefile{toc}{\contentsline {subsubsection}{Stufentherapie}{48}}
\@writefile{toc}{\contentsline {paragraph}{1. Stufe}{48}}
\@writefile{toc}{\contentsline {paragraph}{2. Stufe}{48}}
\@writefile{toc}{\contentsline {paragraph}{3. Stufe}{48}}
\@writefile{toc}{\contentsline {chapter}{\numberline {6}Digitalisglykoside}{49}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {6.1}Herzinsuffizienz}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Ursachen}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Pathogenese und Klinik}{49}}
\@writefile{toc}{\contentsline {paragraph}{Kompensierte Herzinsuffizienz}{49}}
\@writefile{toc}{\contentsline {paragraph}{Dekompensierte Herzinsuffizienz}{49}}
\@writefile{toc}{\contentsline {paragraph}{bei der Diagnosestellung Unterscheidung in}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Symptome}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Klassifikation}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Prognose}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Zur Behandlung der chron. Herzinsuff. eingesetzte Pharmaka}{49}}
\@writefile{toc}{\contentsline {section}{\numberline {6.2}Digitalisglykoside}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmokokinetik}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen / Wechselwirkungen}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Vorgehen bei Digitalisierung}{50}}
\@writefile{toc}{\contentsline {paragraph}{langsame Digitalisierung}{51}}
\@writefile{toc}{\contentsline {paragraph}{mittelschnelle Digitalisierung}{51}}
\@writefile{toc}{\contentsline {subsubsection}{Vergiftung}{51}}
\@writefile{toc}{\contentsline {paragraph}{Zeichen}{51}}
\@writefile{toc}{\contentsline {paragraph}{Therapie}{51}}
\@writefile{toc}{\contentsline {subsubsection}{Stellenwert der Digitalisglykoside}{51}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie der chron. Herzinsuffizienz}{51}}
\@writefile{toc}{\contentsline {paragraph}{nicht medikament\IeC {\"o}s}{51}}
\@writefile{toc}{\contentsline {paragraph}{medikament\IeC {\"o}s}{51}}
\@writefile{toc}{\contentsline {chapter}{\numberline {7}Antiarrhythmika}{52}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {7.1}Mechanismen der Arrhythmieenstehung}{52}}
\@writefile{toc}{\contentsline {subsubsection}{abnorme Schrittmacheraktivit\IeC {\"a}t}{52}}
\@writefile{toc}{\contentsline {subsubsection}{Nachdepolarisation}{52}}
\@writefile{toc}{\contentsline {paragraph}{fr\IeC {\"u}he Nachdepolarisation (EAD)}{52}}
\@writefile{toc}{\contentsline {paragraph}{sp\IeC {\"a}te Nachdepolarisation}{52}}
\@writefile{toc}{\contentsline {subsubsection}{Blockade der Fortleitung}{52}}
\@writefile{toc}{\contentsline {subsubsection}{Reentry}{52}}
\@writefile{toc}{\contentsline {section}{\numberline {7.2}Antiarrhythmika-Klassen (Vaughan-Williams)}{52}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.1}Klasse I-Antiarrhythmika}{52}}
\@writefile{toc}{\contentsline {subsubsection}{Klasse Ia}{53}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{53}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{53}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{53}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{53}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{53}}
\@writefile{toc}{\contentsline {subsubsection}{Klasse Ib}{53}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{53}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{53}}
\@writefile{toc}{\contentsline {paragraph}{Plasma-HWZ}{53}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{53}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{53}}
\@writefile{toc}{\contentsline {subsubsection}{Klasse Ic}{53}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{53}}
\@writefile{toc}{\contentsline {paragraph}{unerw. Wirkungen}{53}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{53}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.2}Klasse II-Antiarrhythmika}{53}}
\@writefile{toc}{\contentsline {subsubsection}{$\beta $-Adrenozeptor-Blocker}{53}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.3}Klasse III-Antiarrhythmika}{54}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{54}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{54}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{54}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{54}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.4}Klasse IV-Antiarrhythmika}{54}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{54}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{54}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{54}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.5}weitere als Antiarrhythmika eingesetzte Pharmaka}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Digitalisglykoside}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Atropin}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Adenosin}{54}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{54}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{54}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{54}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.6}weitere Kardiaka mit Wirkung auf kardiale Kan\IeC {\"a}le}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Ivabradin}{54}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{54}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{54}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{55}}
\@writefile{toc}{\contentsline {section}{\numberline {7.3}Relaxantien glatter Muskulatur}{55}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.3.1}Regulation des Tonus der glatten Muskulatur}{55}}
\@writefile{toc}{\contentsline {subsubsection}{Gef\IeC {\"a}\IeC {\ss }e, Bronchien, Uterus, Magen-Darm-Trakt, Ableitende Harnwege}{55}}
\@writefile{toc}{\contentsline {paragraph}{Regulation \IeC {\"u}ber Rezeptoren}{55}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.3.2}NO-Donatoren}{55}}
\@writefile{toc}{\contentsline {subsubsection}{Organische Nitrate}{55}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{55}}
\@writefile{toc}{\contentsline {paragraph}{Toleranzentwicklung bei organischen Nitraten}{55}}
\@writefile{toc}{\contentsline {paragraph}{Kardiovaskul\IeC {\"a}re Effekte von NO-Donatoren}{55}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmokokinetik}{55}}
\@writefile{toc}{\contentsline {paragraph}{Glyceroltrinitrat}{55}}
\@writefile{toc}{\contentsline {paragraph}{ISDN / ISMN}{56}}
\@writefile{toc}{\contentsline {paragraph}{Natriumnitroprussid}{56}}
\@writefile{toc}{\contentsline {paragraph}{Molsidomin}{56}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{56}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{56}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{56}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{56}}
\@writefile{toc}{\contentsline {section}{\numberline {7.4}Ca$^{2+}$-Kanalblocker}{57}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.4.1}spannungsabh\IeC {\"a}ngige Ca$^{2+}$-Kan\IeC {\"a}le}{57}}
\@writefile{toc}{\contentsline {subsubsection}{Dihydropyridine}{57}}
\@writefile{toc}{\contentsline {subsubsection}{Phenylalkylamine}{57}}
\@writefile{toc}{\contentsline {subsubsection}{Benzothiazepine}{57}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{57}}
\@writefile{toc}{\contentsline {paragraph}{kardiovaskul\IeC {\"a}re Effekte}{58}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{58}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{58}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{58}}
\@writefile{toc}{\contentsline {section}{\numberline {7.5}Koronare Herzkrankheit (KHK)}{58}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.5.1}Pathogenese und Klinik}{58}}
\@writefile{toc}{\contentsline {subsubsection}{Stabile Angina pectoris}{58}}
\@writefile{toc}{\contentsline {subsubsection}{Akutes Koronarsyndrom}{58}}
\@writefile{toc}{\contentsline {subsubsection}{Instabile Angina pectoris}{58}}
\@writefile{toc}{\contentsline {subsubsection}{Nicht ST-Hebungsinfarkt}{58}}
\@writefile{toc}{\contentsline {subsubsection}{ST-Hebungsinfarkt}{58}}
\@writefile{toc}{\contentsline {subsubsection}{Sonderformen}{58}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.5.2}Symptomatische Behandlung der Angina pectoris (A.p.)}{58}}
\@writefile{toc}{\contentsline {subsubsection}{Symptomatische Therapie der A.p. je nach Begleitarkrankungen}{59}}
\@writefile{toc}{\contentsline {subsubsection}{Prognose verbessernde Pharmakotherapie (Mortalit\IeC {\"a}tssenkung)}{59}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.5.3}Therapie des akuten Angina-pectois Anfall}{59}}
\@writefile{toc}{\contentsline {section}{\numberline {7.6}K$^+$-Kanal\IeC {\"o}ffner}{59}}
\@writefile{toc}{\contentsline {subsubsection}{ATP-abh\IeC {\"a}ngiger K$^+$-Kanal}{59}}
\@writefile{toc}{\contentsline {section}{\numberline {7.7}Phosphodiesterase(PDE)-Hemmer}{59}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.7.1}Unselektive PDE-Hemmer}{59}}
\@writefile{toc}{\contentsline {subsubsection}{Methylxanthine}{59}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{59}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{59}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{60}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{60}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{60}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.7.2}Selektive PDE-Hemmer}{60}}
\@writefile{toc}{\contentsline {subsubsection}{PDE 3-Hemmer}{60}}
\@writefile{toc}{\contentsline {subsubsection}{PDE 5-Hemmer}{60}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{60}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{60}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{60}}
\@writefile{toc}{\contentsline {paragraph}{Wechselwirkungen}{60}}
\@writefile{toc}{\contentsline {chapter}{\numberline {8}Antidiabetica}{61}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antidiabetica}{{8}{61}}
\@writefile{toc}{\contentsline {section}{\numberline {8.1}Diabetes mellitus}{61}}
\newlabel{sec:diabetes_mellitus}{{8.1}{61}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.1.1}Typ I Diabetes}{61}}
\newlabel{ssub:typ_i_diabetes}{{8.1.1}{61}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.1.2}Typ II Diabetes}{61}}
\newlabel{ssub:typ_ii_diabetes}{{8.1.2}{61}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.1.3}Sonderformen}{61}}
\newlabel{ssub:sonderformen}{{8.1.3}{61}}
\@writefile{toc}{\contentsline {section}{\numberline {8.2}Insulinsynthese/-sekretion}{61}}
\newlabel{sec:insulinsynthese_sekretion}{{8.2}{61}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.2.1}Insulin-Rezeptor}{61}}
\newlabel{ssub:insulin_rezeptor}{{8.2.1}{61}}
\@writefile{toc}{\contentsline {section}{\numberline {8.3}Insulin}{62}}
\newlabel{sec:insulin}{{8.3}{62}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.1}Kurz-/ultrakurz-wirksame Insuline}{62}}
\newlabel{ssub:kurz_ultrakurz_wirksame_insuline}{{8.3.1}{62}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.2}Mittellang-/lang-wirksame Insuline}{62}}
\newlabel{ssub:mittellang_lang_wirksame_insuline}{{8.3.2}{62}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.3}Kombinations-/Mischinsuline}{62}}
\newlabel{sub:kombinations_mischinsuline}{{8.3.3}{62}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.4}Insulinapplikation}{62}}
\newlabel{ssub:insulinapplikation}{{8.3.4}{62}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.3.4}{62}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{62}}
\@writefile{toc}{\contentsline {section}{\numberline {8.4}Sulfonylharnstoffe}{62}}
\newlabel{sec:sulfonylharnstoffe}{{8.4}{62}}
\newlabel{subp:wirkmechanismus}{{8.4}{63}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{63}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.4.1}ATP-abh\IeC {\"a}ngiger K$^+$-Kanal}{63}}
\newlabel{ssub:atp_abh_ngiger_k_kanal}{{8.4.1}{63}}
\newlabel{subp:pharmakokinetik}{{8.4.1}{63}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{63}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.4.1}{63}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{63}}
\newlabel{subp:interaktionen}{{8.4.1}{63}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{63}}
\newlabel{subp:indikationen}{{8.4.1}{63}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{63}}
\newlabel{subp:kontraindikationen}{{8.4.1}{63}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{63}}
\@writefile{toc}{\contentsline {section}{\numberline {8.5}$\alpha $-Glucosidasehemmer}{63}}
\newlabel{sec:_glucosidasehemmer}{{8.5}{63}}
\newlabel{subp:wirkmechanismus}{{8.5}{63}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{63}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.5}{63}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{63}}
\newlabel{subp:konratindikationen}{{8.5}{63}}
\@writefile{toc}{\contentsline {paragraph}{Konratindikationen}{63}}
\newlabel{subp:indikation}{{8.5}{63}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{63}}
\@writefile{toc}{\contentsline {section}{\numberline {8.6}Biguanide}{63}}
\newlabel{sec:biguanide}{{8.6}{63}}
\newlabel{subp:wirkmechanismus}{{8.6}{64}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{64}}
\newlabel{subp:pharmakokinetik}{{8.6}{64}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{64}}
\newlabel{subp:uner}{{8.6}{64}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{64}}
\newlabel{subp:kontraindikationen}{{8.6}{64}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{64}}
\newlabel{subp:indikationen}{{8.6}{64}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{64}}
\@writefile{toc}{\contentsline {section}{\numberline {8.7}Thiazolidindion-Derivate ("Glitazone")}{64}}
\newlabel{sec:thiazolidindion_derivate_}{{8.7}{64}}
\newlabel{subp:wirkmechanismus}{{8.7}{64}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{64}}
\newlabel{subp:unerw_nschte_wirkung}{{8.7}{64}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkung}{64}}
\newlabel{subp:einsatz}{{8.7}{64}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{64}}
\@writefile{toc}{\contentsline {section}{\numberline {8.8}Glucagon-like-peptide-1(GLP-1)-Agonisten}{64}}
\newlabel{sec:glucagon_like_peptide_1_glp_1_agonisten}{{8.8}{64}}
\newlabel{subp:wirkmechanismus}{{8.8}{64}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{64}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.8}{65}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{65}}
\newlabel{subp:kontraindikationen}{{8.8}{65}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{65}}
\newlabel{subp:einsatz}{{8.8}{65}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{65}}
\@writefile{toc}{\contentsline {section}{\numberline {8.9}Dipeptidyl-Peptidase-IV(DPP-IV)-Hemmer}{65}}
\newlabel{sec:dipeptidyl_peptidase_iv_dpp_iv_hemmer}{{8.9}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{65}}
\newlabel{par:wirkmechanismus}{{8.9}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{65}}
\newlabel{par:unerw_nschte_wirkungen}{{8.9}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{65}}
\newlabel{par:pharmakokinetik}{{8.9}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{65}}
\newlabel{par:einsatz}{{8.9}{65}}
\@writefile{toc}{\contentsline {section}{\numberline {8.10}SGLT2-Inhibitoren}{65}}
\newlabel{sec:sglt2_inhibitoren}{{8.10}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{65}}
\newlabel{par:wirkmechanismus}{{8.10}{65}}
\@writefile{toc}{\contentsline {section}{\numberline {8.11}Diabets-mellitus Behandlung}{65}}
\newlabel{sec:diabets_mellitus_behandlung}{{8.11}{65}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.11.1}Typ I Diabetes}{65}}
\newlabel{ssub:typ_i_diabetes}{{8.11.1}{65}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.11.2}Typ II Diabetes}{65}}
\newlabel{ssub:typ_ii_diabetes}{{8.11.2}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakotherapie}{66}}
\newlabel{par:pharmakotherapie}{{8.11.2}{66}}
\newlabel{subp:nachteil}{{8.11.2}{66}}
\@writefile{toc}{\contentsline {paragraph}{Nachteil}{66}}
\@writefile{toc}{\contentsline {chapter}{\numberline {9}Lipidsenker}{67}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:lipidsenker}{{9}{67}}
\@writefile{toc}{\contentsline {section}{\numberline {9.1}Lipoproteinstoffwechsel}{67}}
\newlabel{sec:lipoproteinstoffwechsel}{{9.1}{67}}
\@writefile{toc}{\contentsline {section}{\numberline {9.2}Fettstoffwechselst\IeC {\"o}rung}{67}}
\newlabel{sec:fettstoffwechselst_rung}{{9.2}{67}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.1}Prim\IeC {\"a}re Hyperlipoprotein\IeC {\"a}mie}{67}}
\newlabel{ssub:prim_re_hyperlipoprotein_mie}{{9.2.1}{67}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.2}Sekund\IeC {\"a}re Hyperlipoprotein\IeC {\"a}mie}{67}}
\newlabel{ssub:sekund_re_h}{{9.2.2}{67}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.3}Bedeutung der Therapie insb. der Hypercholesterin\IeC {\"a}mie}{67}}
\newlabel{ssub:bedeutung_der_therapie_insb_der_hypercholesterin_mie}{{9.2.3}{67}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.4}Therapie}{68}}
\newlabel{ssub:therapie}{{9.2.4}{68}}
\@writefile{toc}{\contentsline {section}{\numberline {9.3}HMG-CoA-Reduktase-Hemmer (Statine)}{68}}
\newlabel{sec:hmg_coa_reduktase_hemmer_}{{9.3}{68}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{68}}
\newlabel{par:wirkmechanismus}{{9.3}{68}}
\newlabel{subp:pleiotrope_wirk}{{9.3}{68}}
\@writefile{toc}{\contentsline {paragraph}{Pleiotrope Wirkungen}{68}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{68}}
\newlabel{par:pharmakokinetik}{{9.3}{68}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{69}}
\newlabel{par:unerw_nschte_wirkungen}{{9.3}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{69}}
\newlabel{par:interaktionen}{{9.3}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{69}}
\newlabel{par:kontraindikationen}{{9.3}{69}}
\@writefile{toc}{\contentsline {section}{\numberline {9.4}Cholesterol-Resorption}{69}}
\newlabel{sec:cholesterol_resorption}{{9.4}{69}}
\@writefile{toc}{\contentsline {section}{\numberline {9.5}Anionen-Austauscher-Harze}{69}}
\newlabel{sec:anionen_austauscher_harze}{{9.5}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{69}}
\newlabel{par:wirkmechanismus}{{9.5}{69}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{69}}
\newlabel{par:unerw_nschte_wirkungen}{{9.5}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Ineraktionen}{69}}
\newlabel{par:ineraktionen}{{9.5}{69}}
\@writefile{toc}{\contentsline {section}{\numberline {9.6}Cholesterinresorptionshemmer}{69}}
\newlabel{sec:cholesterinresorptionshemmer}{{9.6}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{69}}
\newlabel{par:wirkmechanismus}{{9.6}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{69}}
\newlabel{par:pharmakokinetik}{{9.6}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Indikation}{70}}
\newlabel{par:indikation}{{9.6}{70}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{70}}
\newlabel{par:unerw_nschte_wirkungen}{{9.6}{70}}
\@writefile{toc}{\contentsline {section}{\numberline {9.7}Fibrate}{70}}
\newlabel{sec:fibrate}{{9.7}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{70}}
\newlabel{par:wirkmechanismus}{{9.7}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{70}}
\newlabel{par:pharmakokinetik}{{9.7}{70}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{70}}
\newlabel{par:unerw_nschte_wirkungen}{{9.7}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{70}}
\newlabel{par:interaktionen}{{9.7}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{70}}
\newlabel{par:kontrain}{{9.7}{70}}
\@writefile{toc}{\contentsline {section}{\numberline {9.8}Nikotins\IeC {\"a}urederivate}{70}}
\newlabel{sec:nikotins_urederivate}{{9.8}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{70}}
\newlabel{par:wirkmechanismus}{{9.8}{70}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{71}}
\newlabel{par:unerw_nschte_wirkungen}{{9.8}{71}}
\@writefile{toc}{\contentsline {section}{\numberline {9.9}Therapieindikationen bei Hypercholesterin\IeC {\"a}mie}{71}}
\newlabel{sec:therapieindikationen_bei_hypercholesterin_mie}{{9.9}{71}}
\@writefile{toc}{\contentsline {chapter}{\numberline {10}H\IeC {\"o}mostase, Thrombose}{72}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:h_mostase_thrombose}{{10}{72}}
\@writefile{toc}{\contentsline {section}{\numberline {10.1}Thrombozyten-Adh\IeC {\"a}sion/-Aktivierung}{72}}
\newlabel{sec:thrombozyten_adh_sion_aktivierung}{{10.1}{72}}
\@writefile{toc}{\contentsline {section}{\numberline {10.2}Fibrinbildung \IeC {\"u}ber Koagulationskaskade}{72}}
\newlabel{sec:fibrinbildung_ber_koagulationskaskade}{{10.2}{72}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.2.1}Antikoagulatorische Mechanismen}{72}}
\newlabel{ssub:antikoagulatorische_mechanismen}{{10.2.1}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Antithrombin III}{72}}
\newlabel{par:antithrombin_iii}{{10.2.1}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Protein C}{72}}
\newlabel{par:protein_c}{{10.2.1}{72}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.2.2}Pathogenese und Zusammensetzung arterieller und ven\IeC {\"o}ser Thromben}{72}}
\newlabel{ssub:pathogenese_und_zusammensetzung_arterieller_und_ven_ser_thromben}{{10.2.2}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Arterieller Thrombus (wei\IeC {\ss }er Thrombus)}{72}}
\newlabel{par:arterieller_thrombus_wei_er_thrombus_}{{10.2.2}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Ven\IeC {\"o}ser Thrombus (roter Thrombus)}{72}}
\newlabel{par:ven_ser_thrombus_roter_thrombus_}{{10.2.2}{72}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.2.3}Medikament\IeC {\"o}se Beeinflussung}{72}}
\newlabel{ssub:medikament_se_beeinflussung}{{10.2.3}{72}}
\@writefile{toc}{\contentsline {section}{\numberline {10.3}Throbozxtenfunktionshemmer}{73}}
\newlabel{sec:throbozxtenfunktionshemmer}{{10.3}{73}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.3.1}Acetylsalicyls\IeC {\"a}ure(ASS)}{73}}
\newlabel{ssub:acetylsalicyls_ure}{{10.3.1}{73}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{73}}
\newlabel{par:wirkmechan}{{10.3.1}{73}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{73}}
\newlabel{par:paragraph_name}{{10.3.1}{73}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{73}}
\newlabel{par:kontraindikationen}{{10.3.1}{73}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{73}}
\newlabel{par:einsatz}{{10.3.1}{73}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.3.2}Thienopyridine}{73}}
\newlabel{ssub:thienopyridine}{{10.3.2}{73}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{73}}
\newlabel{par:wirkmechan}{{10.3.2}{73}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{73}}
\newlabel{par:unerw_nschte_wirkungen}{{10.3.2}{73}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{73}}
\newlabel{par:einsatz}{{10.3.2}{73}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.3.3}GPIIb/IIIa(Integrin$\alpha $IIb$\beta $3)-Rezeptor-Antagonisten}{73}}
\newlabel{ssub:gpiib_iiia_integrin_iib_3_rezeptor_antagonisten}{{10.3.3}{73}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{73}}
\newlabel{par:wirkmechanismus}{{10.3.3}{73}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{74}}
\newlabel{par:unerw_nschte_wirkung}{{10.3.3}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{74}}
\newlabel{par:einsatz}{{10.3.3}{74}}
\@writefile{toc}{\contentsline {section}{\numberline {10.4}Antikoagulatien}{74}}
\newlabel{sec:section_name}{{10.4}{74}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.1}Vitamin-K-Reduktase-Hemmer (Cumarin-Derivate)}{74}}
\newlabel{ssub:vitamin_k_reduktase_hemmer_}{{10.4.1}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{74}}
\newlabel{par:wirkmechanismus}{{10.4.1}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{74}}
\newlabel{par:pharmakokinetik}{{10.4.1}{74}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{74}}
\newlabel{par:unerw_nschte_wirkungen}{{10.4.1}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{74}}
\newlabel{par:interaktionen}{{10.4.1}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{75}}
\newlabel{par:kontraindikationen}{{10.4.1}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{75}}
\newlabel{par:einsatz}{{10.4.1}{75}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.2}Antithrombin-III-Aktivatoren}{75}}
\newlabel{ssub:antithrombin_iii_aktivatoren}{{10.4.2}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Unfraktioniertes Heparin}{75}}
\newlabel{par:unfraktioniertes_heparin}{{10.4.2}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Niedermolekulares Heparin (z.B. Enoxaparin, Nadroparin, Dalteparin)}{75}}
\newlabel{par:niedermolekulares_heparin_z_b_enoxaparin_nadroparin_dalteparin_}{{10.4.2}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Synthetische Pentasaccharide (z.B. Fondaparinux)}{75}}
\newlabel{par:synthetische_pentasaccharide_z_b_fondaparinux_}{{10.4.2}{75}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{75}}
\newlabel{par:unerw_nschte_wirkungen}{{10.4.2}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{75}}
\newlabel{par:einsatz}{{10.4.2}{75}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.3}Direkte Thrombin-Inhibitoren}{76}}
\newlabel{ssec:direkte_thrombin_inhibitoren}{{10.4.3}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Hirudine}{76}}
\newlabel{par:hirudine}{{10.4.3}{76}}
\@writefile{toc}{\contentsline {subsubsection}{niedermolekulare Thrombin-Inhibitoren}{76}}
\newlabel{par:niedermolekulare_thrombin_inhibitoren}{{10.4.3}{76}}
\newlabel{subp:argatroban}{{10.4.3}{76}}
\@writefile{toc}{\contentsline {paragraph}{Argatroban}{76}}
\newlabel{subp:dagibatranetexilat}{{10.4.3}{76}}
\@writefile{toc}{\contentsline {paragraph}{Dagibatranetexilat}{76}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.4}Direkte Faktor Xa-Inhibitoren}{76}}
\newlabel{ssub:direkte_faktor_xa_inhib}{{10.4.4}{76}}
\@writefile{toc}{\contentsline {subsubsection}{pEinsatz}{76}}
\newlabel{par:paragraph_name}{{10.4.4}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Vorteile}{76}}
\newlabel{par:vorteile}{{10.4.4}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Nachteile}{76}}
\newlabel{par:nachteile}{{10.4.4}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Nutzen}{76}}
\newlabel{par:nutzen}{{10.4.4}{76}}
\@writefile{toc}{\contentsline {section}{\numberline {10.5}Fibrinolytika}{76}}
\newlabel{sec:fibrinolytika}{{10.5}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{76}}
\newlabel{par:wirkmechanismus}{{10.5}{76}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.5.1}Streptokinase}{76}}
\newlabel{ssub:streptokinase}{{10.5.1}{76}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.5.2}Gewebsplasminaktivator (rt-PA / Alteplase)}{76}}
\newlabel{ssub:gewebsplasminaktivator_rt_pa_alteplase_}{{10.5.2}{76}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{77}}
\newlabel{par:unerw_nschte}{{10.5.2}{77}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{77}}
\newlabel{par:einsatz}{{10.5.2}{77}}
\@writefile{toc}{\contentsline {section}{\numberline {10.6}Arterielle Thrombose, Beispiel: Akutes Koronarsyndrom}{77}}
\newlabel{sec:arterielle_thrombose_beispiel_akutes_koronarsyndrom}{{10.6}{77}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.6.1}Instabile Angina pectoris }{77}}
\newlabel{ssub:instabile_angina_pectoris_}{{10.6.1}{77}}
\@writefile{toc}{\contentsline {subsubsection}{wenn Troponin-Test positiv, aber keine ST-Streckenhebung zus\IeC {\"a}tzlich}{77}}
\newlabel{par:wenn_troponin_test_positiv_aber_keine_st_streckenhebung_zus_tzlich}{{10.6.1}{77}}
\@writefile{toc}{\contentsline {subsubsection}{bei eingetretenem Myokardinfarkt zus\IeC {\"a}tzlich}{77}}
\newlabel{par:bei_eingetretenem_myokardinfarkt_zus_tzlich}{{10.6.1}{77}}
\@writefile{toc}{\contentsline {chapter}{\numberline {11}Antiphlogistika}{78}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antiphlogistika}{{11}{78}}
\@writefile{toc}{\contentsline {section}{\numberline {11.1}Nicht-steroidale Antiphlogistika / Antirheumatika (NSAID, NSAR)}{78}}
\newlabel{sec:nicht_steroidale_antiphlogistika_antirheumatika_nsaid_nsar_}{{11.1}{78}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.1}Erw\IeC {\"u}nschte Wirkqualit\IeC {\"a}ten nicht-steroidaler Antiphlogistika}{78}}
\newlabel{ssub:erw_nschte_wirkqualit_ten_nicht_steroidaler_antiphlogistika}{{11.1.1}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Antiphlogistische Wirkung}{78}}
\newlabel{par:antiphlogistische_wirkung}{{11.1.1}{78}}
\newlabel{subp:subparagraph_name}{{11.1.1}{78}}
\@writefile{toc}{\contentsline {paragraph}{Lokale Reaktion}{78}}
\newlabel{subp:subparagraph_name}{{11.1.1}{78}}
\@writefile{toc}{\contentsline {paragraph}{Systemische Reaktion}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Analgetische Wirkung}{78}}
\newlabel{par:analgetische_wirkung}{{11.1.1}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Antipyretische Wirkung}{78}}
\newlabel{par:antipyretische_wirkung}{{11.1.1}{78}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.2}Unerw. Wirkqualit\IeC {\"a}ten nicht-steroidaler Antiphlogistika}{78}}
\newlabel{ssub:unerw_wirkqualit_ten_nicht_steroidaler_antiphlogistika}{{11.1.2}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Gastrointestinal (v.a. COX-1)}{78}}
\newlabel{par:gastrointestinal_v_a_cox_1_}{{11.1.2}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Renal (COX-1 / COX-2)}{79}}
\newlabel{par:renal_cox_1_cox_2_}{{11.1.2}{79}}
\@writefile{toc}{\contentsline {subsubsection}{ Provokation von asthmatischen Beschwerden bei Asthmatikern}{79}}
\newlabel{par:_provokation_von_asthmatischen_beschwerden_bei_asthmatikern}{{11.1.2}{79}}
\@writefile{toc}{\contentsline {subsubsection}{erh\IeC {\"o}htes Risiko f\IeC {\"u}r kardiovaskul\IeC {\"a}re Ereignisse}{79}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.3}Salicylate}{79}}
\newlabel{ssub:salicylate}{{11.1.3}{79}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{79}}
\newlabel{par:einsatz_und_dosierung}{{11.1.3}{79}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{79}}
\newlabel{par:pharmakokinetik}{{11.1.3}{79}}
\@writefile{toc}{\contentsline {subsubsection}{Vergiftung}{79}}
\newlabel{par:vergiftung}{{11.1.3}{79}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{79}}
\newlabel{par:unerw_nschte_wirkungen}{{11.1.3}{79}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{79}}
\newlabel{par:kontraindikationen}{{11.1.3}{79}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.4}Arylessigs\IeC {\"a}uren}{79}}
\newlabel{ssub:arylessigs_uren}{{11.1.4}{79}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{79}}
\newlabel{par:einsatz_und_dosierung}{{11.1.4}{79}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{79}}
\newlabel{par:pharmakokinetik}{{11.1.4}{79}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{79}}
\newlabel{par:unerw_nschte_wirkungen}{{11.1.4}{79}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.5}Arylpropions\IeC {\"a}uren}{80}}
\newlabel{ssub:subsubsection_name}{{11.1.5}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{80}}
\newlabel{par:einsatz_und_dosierung}{{11.1.5}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{80}}
\newlabel{par:pharmakokinetik}{{11.1.5}{80}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.6}Oxicame}{80}}
\newlabel{sub:oxicame}{{11.1.6}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{80}}
\newlabel{par:pharmakokinetik}{{11.1.6}{80}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.7}Selektive COX-2 Hemmer}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkungen}{80}}
\newlabel{par:wirkungen}{{11.1.7}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{80}}
\newlabel{par:indikationen}{{11.1.7}{80}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.8}Langfristig wirksame Antirheumatika (LWAR)}{80}}
\newlabel{sub:langfristig_wirksame_antirheumatika_lwar_}{{11.1.8}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{80}}
\newlabel{par:einsatz}{{11.1.8}{80}}
\@writefile{toc}{\contentsline {subsubsection}{TNF$\alpha $/IL-1-Hemmstoffe}{80}}
\newlabel{par:tnf_alpha_il_1_hemmstoffe}{{11.1.8}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{80}}
\newlabel{par:einsatz}{{11.1.8}{80}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{80}}
\newlabel{par:unerw_nschte_wirkung}{{11.1.8}{80}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.9}Glukokortikoide}{81}}
\newlabel{sub:glukokortikoide}{{11.1.9}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Entz\IeC {\"u}ndungshemmung durch Glukokortikoide}{81}}
\newlabel{par:entz_ndungshemmung_durch_glukokortikoide}{{11.1.9}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Immunsuppression}{81}}
\newlabel{par:immunsuppression}{{11.1.9}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik von Glukokortikoiden}{81}}
\newlabel{par:pharmakokinetik_von_glukokortikoiden}{{11.1.9}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Dosierung / Applikation von Glukokortikoiden}{81}}
\newlabel{par:dosierung_applikation_von_glukokortikoiden}{{11.1.9}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen (Dauertherapie) }{81}}
\newlabel{par:unerw_nschte_wirkungen_dauertherapie_}{{11.1.9}{81}}
\newlabel{subp:oral_lokal}{{11.1.9}{81}}
\@writefile{toc}{\contentsline {paragraph}{oral, lokal}{81}}
\newlabel{subp:inhalativ}{{11.1.9}{82}}
\@writefile{toc}{\contentsline {paragraph}{inhalativ}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Relative Kontraindikationen}{82}}
\newlabel{par:relative_kontraindikationen}{{11.1.9}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Therapeutische Anwendung von Glukokortikoiden}{82}}
\newlabel{par:therapeutische_anwendung_von_glukokortikoiden}{{11.1.9}{82}}
\newlabel{subp:substitutionstherapie}{{11.1.9}{82}}
\@writefile{toc}{\contentsline {paragraph}{Substitutionstherapie}{82}}
\newlabel{subp:_pharmakodynamische_therapie}{{11.1.9}{82}}
\@writefile{toc}{\contentsline {paragraph}{\IeC {\quotedblbase }pharmakodynamische\IeC {\textquotedblleft } Therapie}{82}}
\@writefile{toc}{\contentsline {section}{\numberline {11.2} Pharmakotherapie des Asthma bronchiale (Stufenschema)}{82}}
\newlabel{sec:_pharmakotherapie_des_asthma_bronchiale_stufenschema_}{{11.2}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 1}{82}}
\newlabel{par:stufe_1}{{11.2}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 2}{82}}
\newlabel{par:stufe_2}{{11.2}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 3}{82}}
\newlabel{par:stufe_3}{{11.2}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 4}{82}}
\newlabel{par:stufe_4}{{11.2}{82}}
\@writefile{toc}{\contentsline {chapter}{\numberline {12}Analgetika}{83}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:analgetika}{{12}{83}}
\@writefile{toc}{\contentsline {section}{\numberline {12.1}Nozizeptoren}{83}}
\newlabel{sec:nozizeptoren}{{12.1}{83}}
\@writefile{toc}{\contentsline {subsubsection}{Chronifizierung des Schmerzesbei pathologischen Zust\IeC {\"a}nden: Periphere Sensibilisierung }{83}}
\newlabel{par:chronifizierung_des_schmerzesbei_pathologischen_zust_nden_periphere_sensibilisierung_}{{12.1}{83}}
\@writefile{toc}{\contentsline {section}{\numberline {12.2}Nozizeptive Synapse des Hinterhorns}{83}}
\newlabel{sec:nozizeptive_synapse_des_hinterhorns}{{12.2}{83}}
\@writefile{toc}{\contentsline {subsubsection}{Transmitter exzitatorischer nozizeptiver A$\delta $- un C-Fasern}{83}}
\newlabel{par:transmitter_exzitatorischer_nozizeptiver_a_un_c_fasern}{{12.2}{83}}
\@writefile{toc}{\contentsline {subsubsection}{Chronifizierung des Schmerzes bei pathologischen Zust\IeC {\"a}nden: Zentrale Sensibilisierung }{83}}
\@writefile{toc}{\contentsline {section}{\numberline {12.3}Deszendierendes anti-nozizeptives System}{84}}
\newlabel{sec:deszendierendes_anti_nozizeptives_system}{{12.3}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Periaqu\IeC {\"a}duktales Grau}{84}}
\newlabel{par:periaqu_duktales_grau}{{12.3}{84}}
\@writefile{toc}{\contentsline {section}{\numberline {12.4}Analgetika}{84}}
\newlabel{sec:analgetika}{{12.4}{84}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.1}antiphlogistische/saure Analgetika s. \IeC {\quotedblbase }Antiphlogistika\IeC {\textquotedblleft }}{84}}
\newlabel{sub:subsection_name}{{12.4.1}{84}}
\@writefile{toc}{\contentsline {subsubsection}{erw\IeC {\"u}nschte Wirkqualit\IeC {\"a}ten}{84}}
\newlabel{par:erw_nschte_wirkqualit_tten}{{12.4.1}{84}}
\newlabel{subp:analgetisch}{{12.4.1}{84}}
\@writefile{toc}{\contentsline {paragraph}{analgetisch}{84}}
\@writefile{toc}{\contentsline {subsubsection}{antiphlogistisch / antipyretisch}{84}}
\newlabel{par:antiphlogistisch_antipyretisch}{{12.4.1}{84}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.2}Nicht-saure Analgetika }{84}}
\newlabel{ssub:nicht_saure_analgetika_}{{12.4.2}{84}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.3}Anilinderivate}{84}}
\newlabel{sub:anilinderivate}{{12.4.3}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{84}}
\newlabel{par:einsatz_und_dosierung}{{12.4.3}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{84}}
\newlabel{par:pharmakokinetik}{{12.4.3}{84}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{85}}
\newlabel{par:unerw_nschte_wirkungen}{{12.4.3}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Vergiftung}{85}}
\newlabel{par:vergiftung}{{12.4.3}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Klinik}{85}}
\newlabel{par:klinik}{{12.4.3}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie}{85}}
\newlabel{par:therapie}{{12.4.3}{85}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.4}Pyrazolderivate}{85}}
\newlabel{sub:pyrazolderivate}{{12.4.4}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{85}}
\newlabel{par:einsatz_und_dosierung}{{12.4.4}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{85}}
\newlabel{par:pharmakokinetik}{{12.4.4}{85}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{85}}
\newlabel{par:unerw_nschte_wirkungen}{{12.4.4}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{85}}
\newlabel{par:kontraindikationen}{{12.4.4}{85}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.5}narkotische / opioide Analgetika}{85}}
\newlabel{sub:narkotische_opioide_analgetika}{{12.4.5}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Opioid-Rezeptoren}{85}}
\newlabel{par:opioid_rezeptoren}{{12.4.5}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkungen}{85}}
\newlabel{par:wirkungen}{{12.4.5}{85}}
\newlabel{subp:zentral}{{12.4.5}{85}}
\@writefile{toc}{\contentsline {paragraph}{Zentral}{85}}
\newlabel{subp:peripher}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {paragraph}{Peripher}{86}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{86}}
\newlabel{par:kontraindikationen}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {subsubsection}{wichtige unerw\IeC {\"u}nschte Wirkungen bei Dauerschmerztherapie}{86}}
\newlabel{par:wichtige_unerw_nschte_wirkungen_bei_dauerschmerztherapie}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {subsubsection}{Opiatintoxikation}{86}}
\newlabel{par:opiatintoxikation}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {subsubsection}{Reine Agonisten}{86}}
\newlabel{par:reine_agonisten}{{12.4.5}{86}}
\newlabel{subp:morphin}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {paragraph}{Morphin}{86}}
\newlabel{subp:codein}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {paragraph}{Codein}{86}}
\newlabel{subp:heroin}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {paragraph}{Heroin}{86}}
\@writefile{toc}{\contentsline {subsubsection}{Weitere reine Agonisten}{86}}
\newlabel{subp:weitere_reine_agonisten}{{12.4.5}{86}}
\newlabel{subp:tilidin_und_naloxon}{{12.4.5}{86}}
\@writefile{toc}{\contentsline {paragraph}{Tilidin und Naloxon}{86}}
\@writefile{toc}{\contentsline {subsubsection}{Weitere reine Agonisten}{87}}
\newlabel{par:weitere_reine_agonisten}{{12.4.5}{87}}
\newlabel{subp:levomethadon_methadon}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Levomethadon, Methadon}{87}}
\newlabel{subp:hydromorphon}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Hydromorphon}{87}}
\newlabel{subp:fentanyl}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Fentanyl}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Partielle Agonisten}{87}}
\newlabel{par:partielle_agonisten}{{12.4.5}{87}}
\newlabel{subp:buprenorphin}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Buprenorphin}{87}}
\newlabel{subp:pentazocin}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Pentazocin}{87}}
\@writefile{toc}{\contentsline {subsubsection}{$\mu $-Opioid Agonisten mit hemmender Wirkung auf NA/5-HT-Wiederaufnahme}{87}}
\newlabel{par:_opioid_agonisten_mit_hemmender_wirkung_auf_na_5_ht_wiederaufnahme}{{12.4.5}{87}}
\newlabel{subp:tramadol}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Tramadol}{87}}
\newlabel{subp:tapentadol}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Tapentadol}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Antagonisten}{87}}
\newlabel{par:antagonisten}{{12.4.5}{87}}
\newlabel{subp:naloxon}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Naloxon}{87}}
\newlabel{subp:methylnaltrexon}{{12.4.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Methylnaltrexon}{87}}
\@writefile{toc}{\contentsline {section}{\numberline {12.5}Toleranz, Abh\IeC {\"a}ngigkeit}{87}}
\newlabel{sec:toleranz_abh_ngigkeit}{{12.5}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Toleranz}{87}}
\newlabel{ssub:toleranz}{{12.5}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Abh\IeC {\"a}ngigkeit}{87}}
\newlabel{ssub:abh_ngigkeit}{{12.5}{87}}
\@writefile{toc}{\contentsline {subsubsection}{K\IeC {\"o}rperliche Abh\IeC {\"a}ngigkeit}{87}}
\newlabel{par:k_rperliche_abh_}{{12.5}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Psychische Abh\IeC {\"a}ngigkeit}{87}}
\newlabel{par:psychische_abh_ngigkeit}{{12.5}{87}}
\newlabel{subp:reward_systeme}{{12.5}{87}}
\@writefile{toc}{\contentsline {paragraph}{Reward-Systeme}{87}}
\@writefile{toc}{\contentsline {section}{\numberline {12.6}Koanalgetika / Adjuvantien}{88}}
\newlabel{sec:koanalgetika_adjuvantien}{{12.6}{88}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.6.1}Hemmer neuronaler Natrium und Calcium Kan\IeC {\"a}le}{88}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.6.2}Nicht-selektive Noradrenalin Serotonin Wiederaufnahmehemmer }{88}}
\newlabel{sub:nicht_selektive_noradrenalin_serotonin_wiederaufnahmehemmer_}{{12.6.2}{88}}
\@writefile{toc}{\contentsline {section}{\numberline {12.7}Chronische Schmerzkrankheiten}{88}}
\newlabel{sub:chronische_schme}{{12.7}{88}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.7.1}Stufenplan der WHO f\IeC {\"u}r Behandlung chron. Tumorschmerzen}{88}}
\newlabel{sub:stufenplan_der_who_f_r_behandlung_chron_tumorschmerzen}{{12.7.1}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 1 - Nicht-opioide Analgetika}{88}}
\newlabel{par:stufe_}{{12.7.1}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 2 - Mittelstarke Opiate/Opioide + ggf. nicht-opioide Analgetika}{88}}
\newlabel{par:stufe_}{{12.7.1}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 3 - Starke Opiate/Opioide + ggf. nicht-opioide Analgetika}{88}}
\newlabel{par:stufe_}{{12.7.1}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 4 - Starke Opioide kontinuierlich i.v., s.c., peridural}{88}}
\newlabel{par:stufe_}{{12.7.1}{88}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.7.2}Therapieempfehlung bei chronischen Schmerzen}{89}}
\newlabel{sub:therapieempfehlung_bei_chronischen_schmerzen}{{12.7.2}{89}}
\@writefile{toc}{\contentsline {chapter}{\numberline {13}Sexualhormone}{90}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:sexualhormone}{{13}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{90}}
\newlabel{par:wirkmechanismus}{{13}{90}}
\@writefile{toc}{\contentsline {section}{\numberline {13.1}\IeC {\"O}strogene}{90}}
\newlabel{sec:_strogene}{{13.1}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Nat\IeC {\"u}rliche \IeC {\"O}strogene; geringe Bioverf\IeC {\"u}gbarkeit}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Synthetische \IeC {\"O}strogene}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{90}}
\newlabel{par:indikationen}{{13.1}{90}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{90}}
\newlabel{par:unerw_nschte_wirkung}{{13.1}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{90}}
\newlabel{par:kontraindikationen}{{13.1}{90}}
\@writefile{toc}{\contentsline {section}{\numberline {13.2}Selektive Estrogen-Rezeptor Modulatoren (SERM)}{91}}
\newlabel{sec:selektive_estrogen_rezeptor_modulatoren_serm_}{{13.2}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Clomiphen}{91}}
\newlabel{par:clomiphen}{{13.2}{91}}
\@writefile{toc}{\contentsline {section}{\numberline {13.3}Anti\IeC {\"o}strogene}{91}}
\newlabel{sec:anti_strogene}{{13.3}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Fulvestrant}{91}}
\newlabel{par:fulvestrant}{{13.3}{91}}
\@writefile{toc}{\contentsline {section}{\numberline {13.4}Aromatase-Hemmer}{91}}
\newlabel{sec:aroma}{{13.4}{91}}
\@writefile{toc}{\contentsline {section}{\numberline {13.5}Gestagene}{91}}
\newlabel{sec:gestagene}{{13.5}{91}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.5.1}Synthetische Gestagene}{91}}
\newlabel{sub:synthetische_gestagene}{{13.5.1}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{91}}
\newlabel{subp:indikationen}{{13.5.1}{91}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{91}}
\newlabel{par:unerw_nschte_wirkungen}{{13.5.1}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{91}}
\newlabel{par:kontraindikationen}{{13.5.1}{91}}
\@writefile{toc}{\contentsline {section}{\numberline {13.6}Antigestagene}{92}}
\newlabel{sec:antigestagene}{{13.6}{92}}
\@writefile{toc}{\contentsline {subsubsection}{unerw. Wirkungen}{92}}
\@writefile{toc}{\contentsline {section}{\numberline {13.7}Hormonale Kontrazeptiva (Antikonzeptiva)}{92}}
\newlabel{sec:hormonale_kontrazeptiva_}{{13.7}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{92}}
\newlabel{par:wirkmechanismus}{{13.7}{92}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.7.1}Konzepte}{92}}
\newlabel{sub:konzepte}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Einstufen-Kombinationspr\IeC {\"a}parat}{92}}
\newlabel{par:einstufen_kombinationspr_parat}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Zwei-/Dreistufen-Kombinationspr\IeC {\"a}parat}{92}}
\newlabel{par:zwei_dreistufen_kombinationspr_parat}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Zweiphasen- /Sequenzpr\IeC {\"a}parat}{92}}
\newlabel{par:zweiphasen_sequenzpr_parat}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Monopr\IeC {\"a}parat (\IeC {\quotedblbase }Minipille\IeC {\textquotedblleft })}{92}}
\newlabel{par:monopr_parat_minipille_}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Depot-Gestagene}{92}}
\newlabel{par:depot_gestagene}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{\IeC {\quotedblbase }postkoitale Kontrazeption\IeC {\textquotedblleft }}{92}}
\newlabel{par:_postkoitale_kontrazeption_}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{92}}
\newlabel{par:unerw_nschte_wirkungen}{{13.7.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Gr\IeC {\"u}nde f\IeC {\"u}r \IeC {\quotedblbase }Pillenversager\IeC {\textquotedblleft }}{93}}
\newlabel{par:gr_nde_f_r_pillenversager_}{{13.7.1}{93}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{93}}
\newlabel{par:kontraindikationen}{{13.7.1}{93}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.7.2}Sicherheit verschiedener hormonaler Kontrazeptiva (Pearl-Index)}{93}}
\newlabel{sub:sicherheit_verschiedener_hormonaler_kontrazeptiva_pearl_index_}{{13.7.2}{93}}
\@writefile{toc}{\contentsline {section}{\numberline {13.8}Androgene}{93}}
\newlabel{sec:androgene}{{13.8}{93}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.8.1}seynthetische Androgene}{93}}
\newlabel{sub:seynthetische_androgene}{{13.8.1}{93}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{93}}
\newlabel{par:unerw_nschte_wirkungen}{{13.8.1}{93}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.8.2}Androgenrezeptor-Antagonisten}{93}}
\newlabel{sub:androgenrezeptor_antagonisten}{{13.8.2}{93}}
\@writefile{toc}{\contentsline {subsubsection}{Cyproteronacetat}{93}}
\newlabel{par:cyproteronacetat}{{13.8.2}{93}}
\@writefile{toc}{\contentsline {subsubsection}{Flutamid}{93}}
\newlabel{par:flutamid}{{13.8.2}{93}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.8.3}5$\alpha $-Reduktasehemmer}{93}}
\newlabel{sub:5_alpha_reduktasehemmer}{{13.8.3}{93}}
\@writefile{toc}{\contentsline {subsubsection}{Finasterid}{93}}
\newlabel{par:finasterid}{{13.8.3}{93}}
\@writefile{toc}{\contentsline {chapter}{\numberline {14}Schilddr\IeC {\"u}se}{94}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:schilddr_se}{{14}{94}}
\@writefile{toc}{\contentsline {section}{\numberline {14.1}Schildr\IeC {\"u}senhormone}{94}}
\newlabel{sec:schildr_senhormone}{{14.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Thyroxin (T$_4$)}{94}}
\newlabel{par:thyroxin_t__4_}{{14.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Trijodthyronin (T$_3$)}{94}}
\newlabel{par:trijodthyronin_t__3_}{{14.1}{94}}
\@writefile{toc}{\contentsline {subsection}{\numberline {14.1.1}Bildung}{94}}
\newlabel{sub:bildung}{{14.1.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{94}}
\newlabel{par:wirkmechanismus}{{14.1.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkung}{94}}
\newlabel{par:wirkung}{{14.1.1}{94}}
\@writefile{toc}{\contentsline {section}{\numberline {14.2}Therapeutische Anwendung von L-Tyroxin}{94}}
\newlabel{sec:therapeutische_anwendung_von_l_tyroxin}{{14.2}{94}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{94}}
\newlabel{par:unerw_nschte_wirkungen}{{14.2}{94}}
\@writefile{toc}{\contentsline {subsubsection}{kontraindikationen}{95}}
\newlabel{par:kontraindikationen}{{14.2}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{95}}
\newlabel{par:wechselwirkungen}{{14.2}{95}}
\@writefile{toc}{\contentsline {section}{\numberline {14.3}Thioharnstoff-Derivate / Thionamide}{95}}
\newlabel{sec:thioharnstoff_derivate_thionamide}{{14.3}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{95}}
\newlabel{par:wirkmechanismus}{{14.3}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{95}}
\newlabel{par:pharmakokinetik}{{14.3}{95}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{95}}
\newlabel{par:paragraph_name}{{14.3}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{95}}
\newlabel{par:kontraindikationen}{{14.3}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{95}}
\newlabel{par:indikationen}{{14.3}{95}}
\@writefile{toc}{\contentsline {section}{\numberline {14.4}Iodid-Ionen}{95}}
\newlabel{sec:iodid_ionen}{{14.4}{95}}
\@writefile{toc}{\contentsline {subsection}{\numberline {14.4.1}Kaliumjodid (KJ)}{95}}
\newlabel{sub:kaliumjodid_}{{14.4.1}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{95}}
\newlabel{par:pharmakokinetik}{{14.4.1}{95}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{95}}
\newlabel{par:unerw_nschte_wirkungen}{{14.4.1}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{96}}
\newlabel{par:indikationen}{{14.4.1}{96}}
\@writefile{toc}{\contentsline {section}{\numberline {14.5}Iodprophylaxe}{96}}
\newlabel{sec:iodprophylaxe}{{14.5}{96}}
\@writefile{toc}{\contentsline {chapter}{\numberline {15}Antineoplastika}{97}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antineoplastika}{{15}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Nebenwirkungen der Zytostatikatherapie}{97}}
\newlabel{par:nebenwirkungen_der_zytostatikatherapie}{{15}{97}}
\@writefile{toc}{\contentsline {section}{\numberline {15.1}Antimetabolite}{97}}
\newlabel{sec:antimetabolite}{{15.1}{97}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.1}Hemmer der Dihydrofolatreduktase}{97}}
\newlabel{sub:hemmer_der_dihydrofolatreduktase}{{15.1.1}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{97}}
\newlabel{par:wirkmechanismus}{{15.1.1}{97}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{97}}
\newlabel{par:unerw_nschte_wirkungen}{{15.1.1}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Indikation}{97}}
\newlabel{par:indikation}{{15.1.1}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Besonderes}{97}}
\newlabel{par:besonderes}{{15.1.1}{97}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.2}Antipurine}{97}}
\newlabel{sub:antipurine}{{15.1.2}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{98}}
\newlabel{par:wirkmechanismus}{{15.1.2}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{98}}
\newlabel{par:indikationen}{{15.1.2}{98}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{98}}
\newlabel{par:unerw_nschte_wirkun}{{15.1.2}{98}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.3}Pentostatin}{98}}
\newlabel{sub:pentostatin}{{15.1.3}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{98}}
\newlabel{par:wirkmechanismus}{{15.1.3}{98}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.4}Pyrimidin-Antimetabolite}{98}}
\newlabel{sub:pyrimidin_antimetabolite}{{15.1.4}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{98}}
\newlabel{par:wirkmechanismus}{{15.1.4}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{98}}
\newlabel{par:indikationen}{{15.1.4}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{98}}
\newlabel{ssub:wirkmechanismus}{{15.1.4}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{98}}
\newlabel{ssub:indikationen}{{15.1.4}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{98}}
\newlabel{ssub:wirkmechanismus}{{15.1.4}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{98}}
\newlabel{ssub:indikationen}{{15.1.4}{98}}
\@writefile{toc}{\contentsline {section}{\numberline {15.2}Alkylantien}{98}}
\newlabel{sec:alkylantien}{{15.2}{98}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.2.1}Stickstofflost-Derivate}{98}}
\newlabel{sub:stickstofflost_derivate}{{15.2.1}{98}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{99}}
\newlabel{par:pharmakokinetik}{{15.2.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{99}}
\newlabel{par:unerw_nschte_wirkungen}{{15.2.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{99}}
\newlabel{par:indikationen}{{15.2.1}{99}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.2.2}Platinfreisetzende Verbindungen}{99}}
\newlabel{sub:subsection_name}{{15.2.2}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{99}}
\newlabel{ssub:wirkmechanismus}{{15.2.2}{99}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{99}}
\newlabel{ssub:unerw_nschte_wirkungen}{{15.2.2}{99}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.2.3}Nitrosoharnstoffderivate}{99}}
\newlabel{sub:nitrosoharnstoffderivate}{{15.2.3}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Besonderheiten}{99}}
\newlabel{ssub:besonderheiten}{{15.2.3}{99}}
\@writefile{toc}{\contentsline {subsubsection}{unterw\IeC {\"u}nschte Wirkungen}{99}}
\newlabel{ssub:unterw_nschte_wirkungen}{{15.2.3}{99}}
\@writefile{toc}{\contentsline {section}{\numberline {15.3}Zytostatisch wirksame Antibiotika}{99}}
\newlabel{sec:zytostatisch_wirksame_antibiotika}{{15.3}{99}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.3.1}Anthracycline}{99}}
\newlabel{sub:anthracycline}{{15.3.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{99}}
\newlabel{ssub:wirkmechanismus}{{15.3.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{99}}
\newlabel{ssub:unerw_nschte_wirk}{{15.3.1}{99}}
\@writefile{toc}{\contentsline {section}{\numberline {15.4}Mitosehemmstoffe}{100}}
\newlabel{sec:mitosehemmstoffe}{{15.4}{100}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.4.1}Vinca-Alkaloide}{100}}
\newlabel{sub:vinca_al}{{15.4.1}{100}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{100}}
\newlabel{par:wirkmechanismus}{{15.4.1}{100}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.4.2}Taxane}{100}}
\newlabel{sub:taxane}{{15.4.2}{100}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{100}}
\newlabel{ssub:wirkmechanismus}{{15.4.2}{100}}
\@writefile{toc}{\contentsline {section}{\numberline {15.5}Inhibitoren der Topoisomerase}{100}}
\newlabel{sec:inhibitoren_der_topoisomerase}{{15.5}{100}}
\@writefile{toc}{\contentsline {subsubsection}{Topotectan}{100}}
\newlabel{ssub:topotectan}{{15.5}{100}}
\@writefile{toc}{\contentsline {subsubsection}{Etoposid}{100}}
\newlabel{ssub:etoposid}{{15.5}{100}}
\@writefile{toc}{\contentsline {section}{\numberline {15.6}Hormontherapie}{100}}
\newlabel{sec:hormontherapie}{{15.6}{100}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.6.1}Hormon-sensitives Mammakarzinom }{100}}
\newlabel{sub:hormon_sensitives_mammakarzinom_}{{15.6.1}{100}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.6.2}Hormonsensitives Prostatakarzinom}{100}}
\newlabel{sub:hormonsensitives_prostatakarzinom}{{15.6.2}{100}}
\@writefile{toc}{\contentsline {section}{\numberline {15.7}Tyrosinkinase-Hemmer}{101}}
\newlabel{sec:tyrosinkinase_hemmer}{{15.7}{101}}
\@writefile{toc}{\contentsline {section}{\numberline {15.8}Protease-Inhibitor}{101}}
\newlabel{sec:protease_inhibitor}{{15.8}{101}}
\@writefile{toc}{\contentsline {section}{\numberline {15.9}Antik\IeC {\"o}rper}{101}}
\newlabel{sec:antik_rper}{{15.9}{101}}
\@writefile{toc}{\contentsline {section}{\numberline {15.10}Resistenzentwicklungen}{101}}
\newlabel{sec:resistenzentwicklungen}{{15.10}{101}}
\@writefile{toc}{\contentsline {chapter}{\numberline {16}Toxikologie}{102}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:toxikologie}{{16}{102}}
\@writefile{toc}{\contentsline {section}{\numberline {16.1}Behandlungsprinzipien akuter Intoxikationen}{102}}
\newlabel{sec:behandlungsprinzipien_akuter_intoxikationen}{{16.1}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Hemmung von Resorption}{102}}
\newlabel{ssub:hemmung_von_resorption}{{16.1}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Induziertes Erbrechen nie bei}{102}}
\newlabel{ssub:induziertes_erbrechen_nie_bei}{{16.1}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Beschleunighte Giftelimination}{102}}
\newlabel{ssub:beschleunighte_giftelimination}{{16.1}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Antidote}{102}}
\newlabel{ssub:antidote}{{16.1}{102}}
\@writefile{toc}{\contentsline {section}{\numberline {16.2}Gase}{103}}
\newlabel{sec:gase}{{16.2}{103}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.1}Reizgase}{103}}
\newlabel{sub:reizgase}{{16.2.1}{103}}
\@writefile{toc}{\contentsline {subsubsection}{Toxisches Lungen\IeC {\"o}dem}{103}}
\newlabel{ssub:toxisches_lungen_dem}{{16.2.1}{103}}
\newlabel{par:therapie}{{16.2.1}{103}}
\@writefile{toc}{\contentsline {paragraph}{Therapie}{103}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.2}Systemisch wirkende Gase}{103}}
\newlabel{sub:systemisch_wirkende_gase}{{16.2.2}{103}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.3}Meth\IeC {\"a}moglobinbildner}{103}}
\newlabel{sub:meth_moglobinbildner}{{16.2.3}{103}}
\@writefile{toc}{\contentsline {subsubsection}{Mechanismus}{103}}
\newlabel{ssub:mechanismus}{{16.2.3}{103}}
\@writefile{toc}{\contentsline {subsubsection}{Klinik}{103}}
\newlabel{ssub:klinik}{{16.2.3}{103}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie}{104}}
\newlabel{ssub:therapie}{{16.2.3}{104}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.4}Metalle}{104}}
\newlabel{sub:metalle}{{16.2.4}{104}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.5}S\IeC {\"a}uren, Laugen, Tenside, L\IeC {\"o}sungsmittel}{105}}
\newlabel{sub:s_uren_laugen_tenside_l_sungsmittel}{{16.2.5}{105}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.6}Halogenierte aromatische Kohlenwasserstoffe: Polychlorierte Dibenzodioxine und -furane}{105}}
\newlabel{sub:halogenierte_aromatische_kohlenwasserstoffe_polychlorierte_dibenzodioxine_und_furane}{{16.2.6}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Entstehung}{105}}
\newlabel{ssub:entstehung}{{16.2.6}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Kinetik}{105}}
\newlabel{ssub:kinetik}{{16.2.6}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkung}{105}}
\newlabel{ssub:wirkung}{{16.2.6}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Toxische Wirkung}{105}}
\newlabel{ssub:toxische_wirkung}{{16.2.6}{105}}
\@writefile{lof}{\contentsline {figure}{\numberline {16.1}{\ignorespaces Blutethanol Berechnung VD$_{M\mathaccentV {ddot}07F{a}nner}$ = 0,7 VD$_{Frauen}$ = 0,6\relax }}{106}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.7}Bakterielle Toxine}{106}}
\newlabel{sub:bakterielle_toxine}{{16.2.7}{106}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.8}Alkohole (Methanol, Ethanol)}{106}}
\newlabel{sub:alkohole_}{{16.2.8}{106}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{106}}
\newlabel{ssub:pharmakokinetik}{{16.2.8}{106}}
\@writefile{toc}{\contentsline {subsubsection}{akute Effekte Ethanol}{106}}
\newlabel{ssub:akute_effekte_ethanol}{{16.2.8}{106}}
\@writefile{toc}{\contentsline {subsubsection}{chronische Effekte Ethanol}{107}}
\newlabel{ssub:chronische_effekte_ethanol}{{16.2.8}{107}}
\@writefile{toc}{\contentsline {subsubsection}{akute Effekte Methanol}{107}}
\newlabel{ssub:akute_effekte_methanol}{{16.2.8}{107}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.9}Tabakrauch}{107}}
\newlabel{sub:tabakrauch}{{16.2.9}{107}}
\@writefile{toc}{\contentsline {subsubsection}{Tabakrauch}{107}}
\newlabel{ssub:subsubsection_name}{{16.2.9}{107}}
\@writefile{toc}{\contentsline {subsubsection}{akute Wirkung v.a. Nikotin}{107}}
\newlabel{ssub:akute_wirkung_v_a_nikotin}{{16.2.9}{107}}
\@writefile{toc}{\contentsline {subsubsection}{chronische Wirkung}{107}}
\newlabel{ssub:chronische_wirkung}{{16.2.9}{107}}
\@writefile{toc}{\contentsline {section}{\numberline {16.3}Krebserzeugende Stoffe}{107}}
\newlabel{sec:krebserzeugende_stoffe}{{16.3}{107}}
\@writefile{toc}{\contentsline {subsubsection}{Polycyclische aromatische Kohlenwasserstoffe: Benzo(a)pyren, Benzo(a)athracen}{107}}
\newlabel{ssub:polycyclische_aromatische_kohlenwasserstoffe_benzo}{{16.3}{107}}
\@writefile{toc}{\contentsline {subsubsection}{Entstehung}{107}}
\newlabel{ssub:entstehung}{{16.3}{107}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{107}}
\newlabel{ssub:pharmakokinetik}{{16.3}{107}}
\@writefile{toc}{\contentsline {subsubsection}{Chronische Toxizit\IeC {\"a}t}{107}}
\newlabel{ssub:chronische_toxizit_t}{{16.3}{107}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.3.1}Nitrosamine / Nitrosamide}{107}}
\newlabel{sub:nitrosamine_nitrosamide}{{16.3.1}{107}}
\@writefile{toc}{\contentsline {subsubsection}{Exogene Enstehung}{107}}
\newlabel{ssub:subsubsection_name}{{16.3.1}{107}}
\@writefile{toc}{\contentsline {subsubsection}{Endogene Entstehung}{108}}
\newlabel{ssub:endogene_entstehung}{{16.3.1}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkung}{108}}
\newlabel{ssub:wirkung}{{16.3.1}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Toxizit\IeC {\"a}t}{108}}
\newlabel{ssub:akute_toxizit_t}{{16.3.1}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Andere krebserzeugende Substanzen}{108}}
\newlabel{ssub:andere_krebserzeugende_substanzen_aromatische_amine_gegrilltes_fleisch_tabakrauch_aflatoxine_metalle_ni_cr_as_}{{16.3.1}{108}}
\@writefile{toc}{\contentsline {section}{\numberline {16.4}Pilzgifte}{108}}
\newlabel{sec:pilzgifte}{{16.4}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Niedere Pilze (Ascomyceten)}{108}}
\newlabel{ssub:niedere_pilze_ascomyceten_}{{16.4}{108}}
\@writefile{toc}{\contentsline {subsubsection}{H\IeC {\"o}here Pilze (Basidiomyceten)}{108}}
\newlabel{ssub:h_here_pilze_basidiomyceten_}{{16.4}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Fliegenpilz (Amanita muscaria); Pantherpilz (Amanita pantherina)}{108}}
\newlabel{ssub:subsubsection_name}{{16.4}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Risspilze (Inocybe \IeC {\textendash } Arten)}{108}}
\newlabel{ssub:risspilze_inocybe_arten_}{{16.4}{108}}
\@writefile{toc}{\contentsline {section}{\numberline {16.5}Chemische Kampfstoffe}{108}}
\newlabel{sec:chemische_kampfstoffe}{{16.5}{108}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.5.1}Organophosphate}{108}}
\newlabel{sub:organophosphate}{{16.5.1}{108}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.5.2}Alkylatien}{108}}
\newlabel{sub:alkylatien}{{16.5.2}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Symptomatik}{109}}
\newlabel{ssub:symptomatik}{{16.5.2}{109}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie}{109}}
\newlabel{ssub:therapie}{{16.5.2}{109}}
\@writefile{toc}{\contentsline {section}{\numberline {16.6}Wichtige Intoxikationen}{109}}
\newlabel{sec:wichtige_intoxikationen}{{16.6}{109}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.6.1}Typische Vergiftungssyndrome}{109}}
\newlabel{sub:typische_vergiftungssyndrome}{{16.6.1}{109}}
\@writefile{toc}{\contentsline {chapter}{\numberline {17}Antiinfektiva}{110}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antiinfektiva}{{17}{110}}
\@writefile{toc}{\contentsline {section}{\numberline {17.1}Antibakterielle Wirkstoffe}{110}}
\newlabel{sec:antibakterielle_wirkstoffe}{{17.1}{110}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.1}Definitionen}{110}}
\newlabel{sub:definitonen}{{17.1.1}{110}}
\newlabel{par:chemotherapeutika}{{17.1.1}{110}}
\@writefile{toc}{\contentsline {paragraph}{Chemotherapeutika}{110}}
\newlabel{par:antibiotika}{{17.1.1}{110}}
\@writefile{toc}{\contentsline {paragraph}{Antibiotika}{110}}
\newlabel{par:bakteriostase}{{17.1.1}{110}}
\@writefile{toc}{\contentsline {paragraph}{Bakteriostase}{110}}
\newlabel{par:bakterizidie}{{17.1.1}{110}}
\@writefile{toc}{\contentsline {paragraph}{Bakterizidie}{110}}
\newlabel{par:mhk_mic_minimale_hemmkonzentration}{{17.1.1}{110}}
\@writefile{toc}{\contentsline {paragraph}{MHK (MIC) - minimale Hemmkonzentration}{110}}
\newlabel{par:mbk_mbc_minimale_bakterizide_konzentration}{{17.1.1}{110}}
\@writefile{toc}{\contentsline {paragraph}{MBK (MBC) - minimale bakterizide Konzentration}{110}}
\newlabel{par:pae_postantibiotischer_effekt}{{17.1.1}{110}}
\@writefile{toc}{\contentsline {paragraph}{PAE - Postantibiotischer Effekt}{110}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.2}Hemmstoffe der Tretrahdrofols\IeC {\"a}ure-Synthese}{110}}
\newlabel{sub:hemmstoffe_der_tretrahdrofols_ure_synthese}{{17.1.2}{110}}
\@writefile{toc}{\contentsline {subsubsection}{Sufonamide (Sulfamethoxazol)}{110}}
\newlabel{ssub:sufonamide_sulfamethoxazol_}{{17.1.2}{110}}
\newlabel{par:wirkmechanismus}{{17.1.2}{110}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{110}}
\newlabel{par:nebenwirkungen}{{17.1.2}{110}}
\@writefile{toc}{\contentsline {paragraph}{Nebenwirkungen}{110}}
\@writefile{toc}{\contentsline {subsubsection}{Diaminopyridine Trimethoprim}{110}}
\newlabel{ssub:diaminopyridine}{{17.1.2}{110}}
\newlabel{par:wirkmechanismus}{{17.1.2}{110}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{110}}
\newlabel{par:nebenwirkungen}{{17.1.2}{110}}
\@writefile{toc}{\contentsline {paragraph}{Nebenwirkungen}{110}}
\newlabel{par:indikationen}{{17.1.2}{110}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{110}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.3}Hemmstoffe der bakteriellen Zellwandsynthese}{110}}
\newlabel{sub:hemmstoffe_der_bakteriellen_zellwandsynthese}{{17.1.3}{110}}
\@writefile{toc}{\contentsline {subsubsection}{$\beta $-Lactame: Penicilline, Cephalosporine, atypische Laktame}{111}}
\newlabel{ssub:subsubsection_name}{{17.1.3}{111}}
\newlabel{par:wirkmechanismus}{{17.1.3}{111}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{111}}
\@writefile{toc}{\contentsline {subsubsection}{Benzylpenicilline}{111}}
\newlabel{ssub:benzylpenicilline}{{17.1.3}{111}}
\@writefile{toc}{\contentsline {subsubsection}{Oral-Penicilline}{111}}
\newlabel{ssub:oral_penicilline}{{17.1.3}{111}}
\newlabel{par:vorteile}{{17.1.3}{111}}
\@writefile{toc}{\contentsline {paragraph}{Vorteile}{111}}
\@writefile{toc}{\contentsline {subsubsection}{Isoazolyl-Penicilline}{111}}
\newlabel{ssub:isoazolyl_penicilline}{{17.1.3}{111}}
\@writefile{toc}{\contentsline {subsubsection}{Amiopenicilline}{112}}
\newlabel{ssub:amiopenicilline}{{17.1.3}{112}}
\@writefile{toc}{\contentsline {subsubsection}{Penicilline mit erweitertem Spektrum (Gram -)}{112}}
\newlabel{par:acylaminopenicilline}{{17.1.3}{112}}
\@writefile{toc}{\contentsline {paragraph}{Acylaminopenicilline}{112}}
\newlabel{par:paragraph_name}{{17.1.3}{112}}
\@writefile{toc}{\contentsline {paragraph}{$\beta $-Lactamasehemmer}{112}}
\@writefile{toc}{\contentsline {subsubsection}{Cephalosporine}{112}}
\newlabel{ssub:cephalosporine}{{17.1.3}{112}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.4}Hemmstoffe der bakteriellen Proteinsynthese}{112}}
\newlabel{sub:hemmstoffe_der_bakteriellen_proteinsynthese}{{17.1.4}{112}}
\@writefile{toc}{\contentsline {subsubsection}{Aminoglykoside}{112}}
\newlabel{ssub:aminoglykoside}{{17.1.4}{112}}
\@writefile{toc}{\contentsline {subsubsection}{Tetracycline}{113}}
\newlabel{ssub:tetracycline}{{17.1.4}{113}}
\@writefile{toc}{\contentsline {subsubsection}{Glycycycline}{113}}
\newlabel{ssub:glycycycline}{{17.1.4}{113}}
\@writefile{toc}{\contentsline {subsubsection}{Makrolide}{113}}
\newlabel{ssub:makrolide}{{17.1.4}{113}}
\@writefile{toc}{\contentsline {subsubsection}{Chinolone - Gyrasehemmer}{113}}
\newlabel{ssub:chinolone_gyrasehemmer}{{17.1.4}{113}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.5}Resistenzmechanismen}{114}}
\newlabel{sub:subsection_name}{{17.1.5}{114}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.6}Reserve-Antibiotika}{114}}
\newlabel{sub:reserve_antibiotika}{{17.1.6}{114}}
\@writefile{toc}{\contentsline {subsubsection}{Mit sehr breitem Spektrum}{114}}
\newlabel{ssub:mit_sehr_breitem_spektrum}{{17.1.6}{114}}
\@writefile{toc}{\contentsline {subsubsection}{Mit sehr selektivem Spektrum}{114}}
\newlabel{ssub:mit_sehr_selektivem_spektrum}{{17.1.6}{114}}
\@writefile{toc}{\contentsline {section}{\numberline {17.2}Tuberkulosemittel}{115}}
\newlabel{sec:tuberkulosemittel}{{17.2}{115}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.2.1}Kurzzeittherapie}{115}}
\newlabel{sub:kurzzeittherapie}{{17.2.1}{115}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.2.2}Langzeittherapie}{115}}
\newlabel{sub:langzeittherapie}{{17.2.2}{115}}
\@writefile{toc}{\contentsline {section}{\numberline {17.3}Antimykotika}{115}}
\newlabel{sec:antimykotika}{{17.3}{115}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.3.1}Allylamine (Squalenepoxidase-Hemmer)}{115}}
\newlabel{sub:allylamine_squalenepoxidase_hemmer_}{{17.3.1}{115}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.3.2}Azol-Antimykotika (Lanosterin-Demethylase-Hemmer)}{115}}
\newlabel{sub:azol_antimykotika_lanosterin_demethylase_hemmer_}{{17.3.2}{115}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.3.3}Polyen-Antimykotika}{115}}
\newlabel{sub:polyen_antimykotika}{{17.3.3}{115}}
\@writefile{toc}{\contentsline {section}{\numberline {17.4}Prophylaxe und Therapie der Malaria}{115}}
\newlabel{sec:prophylaxe_und_therapie_der_malaria}{{17.4}{115}}
\@writefile{toc}{\contentsline {section}{\numberline {17.5}Virustatika}{116}}
\newlabel{sec:virustatika}{{17.5}{116}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.5.1}Antimetabolite}{116}}
\newlabel{sub:antimetabolite}{{17.5.1}{116}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.5.2}Antiretrovirale Therapie}{116}}
\newlabel{sub:antiretrovirale_therapie}{{17.5.2}{116}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiel Initialtherapie bei HIV}{116}}
\newlabel{ssub:beispiel_initialtherapie_bei_hiv}{{17.5.2}{116}}
\newlabel{par:mimbranfusionshemmer}{{17.5.2}{116}}
\@writefile{toc}{\contentsline {paragraph}{Mimbranfusionshemmer}{116}}
\newlabel{par:neuramidasehemmer}{{17.5.2}{116}}
\@writefile{toc}{\contentsline {paragraph}{Neuramidasehemmer}{116}}
\@writefile{toc}{\contentsline {chapter}{\numberline {18}Hypnotika}{117}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:hypnotika}{{18}{117}}
\@writefile{toc}{\contentsline {section}{\numberline {18.1}$\gamma $-Aminobutters\IeC {\"a}ure (GABA)}{117}}
\newlabel{sec:section_name}{{18.1}{117}}
\@writefile{toc}{\contentsline {subsection}{\numberline {18.1.1}GABA-Rezeptoren}{117}}
\newlabel{sub:gaba_rezeptoren}{{18.1.1}{117}}
\@writefile{toc}{\contentsline {subsubsection}{GABA$_A-Rezeptor$}{117}}
\newlabel{ssub:gaba__a_}{{18.1.1}{117}}
\@writefile{toc}{\contentsline {subsubsection}{GABA$_B$-Rezeptor}{117}}
\newlabel{ssub:gaba__b_rezeptor}{{18.1.1}{117}}
\@writefile{toc}{\contentsline {section}{\numberline {18.2}Benzodiazipine}{118}}
\newlabel{sec:benzodiazipine}{{18.2}{118}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkprofil}{118}}
\newlabel{ssub:wirkprofil}{{18.2}{118}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{118}}
\newlabel{ssub:pharmakokinetik}{{18.2}{118}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{118}}
\newlabel{ssub:unerw_nschte_wirkungen}{{18.2}{118}}
\@writefile{toc}{\contentsline {subsubsection}{Abh\IeC {\"a}ngigkeit und Toleranz}{118}}
\newlabel{ssub:abh_ngigkeit_und_toleranz}{{18.2}{118}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{119}}
\newlabel{ssub:akute_vergiftung}{{18.2}{119}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{119}}
\newlabel{ssub:wechselwirkungen}{{18.2}{119}}
\@writefile{toc}{\contentsline {subsection}{\numberline {18.2.1}Zyklopyrrolone (Zopiclon); Imidazopyridine (Zolpidem); Pyrazolopyrimidine (Zaleplon)}{119}}
\newlabel{sub:zyklopyrrolone_zopiclon_imidazopyridine_zolpidem_pyrazolopyrimidine_zaleplon_}{{18.2.1}{119}}
\@writefile{toc}{\contentsline {section}{\numberline {18.3}Behandlung von Schlafst\IeC {\"o}rungen}{119}}
\newlabel{sec:behandlung_von_schlafst_rungen}{{18.3}{119}}
\@writefile{toc}{\contentsline {subsubsection}{\IeC {\quotedblbase }Vier-K-Regel\IeC {\textquotedblleft } (nach Borb\IeC {\'e}ly, 1986)}{119}}
\newlabel{ssub:_vier_k_regel_nach_borb_ly_1986_}{{18.3}{119}}
\@writefile{toc}{\contentsline {subsection}{\numberline {18.3.1}Empfehlungen der Deutschen Gesellschaft f\IeC {\"u}r Schlafforschung und Schlafmedizin zur Anwendung von Benzodiazepinen}{119}}
\newlabel{sub:subsection_name}{{18.3.1}{119}}
\@writefile{toc}{\contentsline {chapter}{\numberline {19}Narkotika}{120}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:narkotika}{{19}{120}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{120}}
\newlabel{ssub:wirkmechanismus}{{19}{120}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.0.2}Inhalationsnarkotika}{120}}
\newlabel{sub:inhalationsnarkotika}{{19.0.2}{120}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{120}}
\newlabel{ssub:pharmakokinetik}{{19.0.2}{120}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.0.3}Isofluran, Desfluran, Sevofluran}{121}}
\newlabel{sub:isofluran_desfluran_sevofluran}{{19.0.3}{121}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.0.4}Lachgas / N$_2$O / Stickoxydul}{121}}
\newlabel{sub:lachgas_n__2_o_stickoxydul}{{19.0.4}{121}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{121}}
\newlabel{ssub:wirkmechanismus}{{19.0.4}{121}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{121}}
\newlabel{ssub:unerw_nschte_wirkungen}{{19.0.4}{121}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{121}}
\newlabel{ssub:einsatz}{{19.0.4}{121}}
\@writefile{toc}{\contentsline {section}{\numberline {19.1}Injektionsnarkotika}{121}}
\newlabel{sec:injektionsnarkotika}{{19.1}{121}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.1}Barbiturate}{122}}
\newlabel{sub:barbiturate}{{19.1.1}{122}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.2}Ketamin}{122}}
\newlabel{sub:ketamin}{{19.1.2}{122}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.3}Etomidat}{122}}
\newlabel{ssub:etomidat}{{19.1.3}{122}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.4}Propofol}{122}}
\newlabel{sub:propofol}{{19.1.4}{122}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.5}Benzodiazepine}{122}}
\newlabel{sub:benzodiazepine}{{19.1.5}{122}}
\@writefile{toc}{\contentsline {section}{\numberline {19.2}Kombinationsnarkose (Beispiel)}{123}}
\newlabel{sec:kombinationsnarkose_}{{19.2}{123}}
\@writefile{toc}{\contentsline {subsubsection}{Pr\IeC {\"a}medikation}{123}}
\newlabel{ssub:pr_medikation}{{19.2}{123}}
\@writefile{toc}{\contentsline {subsubsection}{Einleitung}{123}}
\newlabel{ssub:einleitung}{{19.2}{123}}
\@writefile{toc}{\contentsline {subsubsection}{Ausleitung}{123}}
\newlabel{ssub:ausleitung}{{19.2}{123}}
\@writefile{toc}{\contentsline {chapter}{\numberline {20}Anti-Parkinsonmittel}{124}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:anti_parkinsonmittel}{{20}{124}}
\@writefile{toc}{\contentsline {section}{\numberline {20.1}Dopaminerges System}{124}}
\newlabel{sec:dopaminerges_system}{{20.1}{124}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.1.1}Dopaminerge Synapse}{124}}
\newlabel{sub:dopaminerge_synapse}{{20.1.1}{124}}
\newlabel{par:dopaminerge_rezeptoren}{{20.1.1}{124}}
\@writefile{toc}{\contentsline {paragraph}{Dopaminerge Rezeptoren}{124}}
\newlabel{par:dopaminerge_systeme}{{20.1.1}{124}}
\@writefile{toc}{\contentsline {paragraph}{Dopaminerge Systeme}{124}}
\@writefile{toc}{\contentsline {section}{\numberline {20.2}Morbus Parkinson}{124}}
\newlabel{sec:morbus_parkinson}{{20.2}{124}}
\@writefile{toc}{\contentsline {section}{\numberline {20.3}Extrapyramidales System / Basalganglien}{124}}
\newlabel{sec:extrapyramidales_system_basalganglien}{{20.3}{124}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.3.1}Funktionskreis}{124}}
\newlabel{sub:funktionskreis}{{20.3.1}{124}}
\@writefile{toc}{\contentsline {subsubsection}{Thalamus \IeC {\textendash } Cortex \IeC {\textendash } Basalganglien}{124}}
\newlabel{ssub:subsubsection_name}{{20.3.1}{124}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.3.2}Direkter Weg}{125}}
\newlabel{sub:ditekter_weg}{{20.3.2}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Striatum $\rightarrow $ Globus pallidus med. $\rightarrow $ Thalamus }{125}}
\newlabel{ssub:subsubsection_name}{{20.3.2}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Indirekter Weg: Striatum $\rightarrow $ Globus pallidus lat. $\rightarrow $ Ncl. Subthalam. $\rightarrow $ Thalamus}{125}}
\newlabel{ssub:indirekter_weg_striatum_globus_pallidus_lat_ncl_subthalam_thalamus}{{20.3.2}{125}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.3.3}Bei M.Parkinson}{125}}
\newlabel{sub:bei_m_parkinson}{{20.3.3}{125}}
\@writefile{toc}{\contentsline {section}{\numberline {20.4}Therapie des Morbus Parkinson}{125}}
\newlabel{sec:therapie_des_morbus_parkinson}{{20.4}{125}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.1}Erh\IeC {\"o}hung der striatalen Dopaminkonz. durch Gabe von L-Dopa sowie d. Hemmung des Dopaminabbaus (MAO$_B$/COMT-Hemmer)}{125}}
\newlabel{sub:erh_hung_der_striatalen_dopaminkonz_durch_gabe_von_l_dopa_sowie_d_hemmung_des_dopaminabbaus_mao__b_comt_hemmer_}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Levodopa (L-Dopa)}{125}}
\newlabel{ssub:levodopa_}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Dopa-Decarboxylase-Hemmer}{125}}
\newlabel{ssub:dopa_decarboxylase_hemmer}{{20.4.1}{125}}
\newlabel{par:paragraph_name}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {paragraph}{Wirkungseinschr\IeC {\"a}nkung}{125}}
\newlabel{par:paragraph_name}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {paragraph}{Wirkungsfluktuation / on-off-Ph\IeC {\"a}nomen}{125}}
\newlabel{par:paragraph_name}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {paragraph}{Dyskinesien}{125}}
\newlabel{par:paragraph_name}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {paragraph}{unerw. Wirkungen}{125}}
\newlabel{par:einsatz}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Monoaminoxidase B Hemmer}{125}}
\newlabel{ssub:monoaminoxidase_b_hemmer}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Catecho-O-Methyltransferase(COMT)-Hemmer}{126}}
\newlabel{ssub:catecho_o_methyltransferase_}{{20.4.1}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.2}Direkte Stimulation zentraler Dopaminrezeptoren}{126}}
\newlabel{sub:direkte_stimulation_zentraler_dopaminrezeptoren}{{20.4.2}{126}}
\@writefile{toc}{\contentsline {subsubsection}{Dopamin-Rezeptoragonisten}{126}}
\newlabel{ssub:dopamin_rezeptoragonisten}{{20.4.2}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.3}Hemmung zentraler muscarinischer Rezeptoren}{126}}
\newlabel{sub:hemmung_zentraler_muscarinischer_rezeptoren}{{20.4.3}{126}}
\@writefile{toc}{\contentsline {subsubsection}{Muskarinrezeptor-Antagonisten}{126}}
\newlabel{ssub:muskarinrezeptor_antagonisten}{{20.4.3}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.4}Blockade von Glutamat-Rezepotoren (NMDA-Typ)}{126}}
\newlabel{sub:blockade_von_glutamat_rezepotoren_}{{20.4.4}{126}}
\@writefile{toc}{\contentsline {subsubsection}{NMDA Rezeptor-Antagonisten}{126}}
\newlabel{ssub:nmda_rezeptor_antagonisten}{{20.4.4}{126}}
\@writefile{toc}{\contentsline {chapter}{\numberline {21}Antiepileptika}{127}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antiepileptika}{{21}{127}}
\@writefile{toc}{\contentsline {section}{\numberline {21.1}Formen der Epilepsie}{127}}
\newlabel{sec:formen_der_epilepsie}{{21.1}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.1.1}Fokal}{127}}
\newlabel{sub:fokal}{{21.1.1}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.1.2}Pim\IeC {\"a}r generalisiert}{127}}
\newlabel{sub:pim_r_generalisiert}{{21.1.2}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.1.3}Nicht klassifizierbar}{127}}
\newlabel{sub:nicht_klassifizierbar}{{21.1.3}{127}}
\@writefile{toc}{\contentsline {section}{\numberline {21.2}Pathomechanismen der Epilepsie}{127}}
\newlabel{sec:pathomechanismen_der_epilepsie}{{21.2}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.2.1}Zellul\IeC {\"a}res Korrelat}{127}}
\newlabel{sub:zellul_res_korrelat}{{21.2.1}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.2.2}Versagen der Umfeldhemmung}{127}}
\newlabel{sub:versagen_der_umfeldhemmung}{{21.2.2}{127}}
\@writefile{toc}{\contentsline {section}{\numberline {21.3}Antiepileptika}{128}}
\newlabel{sec:antiepileptika}{{21.3}{128}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.1}Hemmung der Erregbarkeit von Neuronen}{128}}
\newlabel{sub:hemmung_der_erregbarkeit_von_neuronen}{{21.3.1}{128}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.2}Verst\IeC {\"a}rkung der Umfeldhemmung epileptisch aktiver Neurone}{128}}
\newlabel{sub:verst_rkung_der_umfeldhemmung_epileptisch_aktiver_neurone}{{21.3.2}{128}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.3}Pharmaka}{128}}
\newlabel{sub:pharmaka}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Pheytoin}{128}}
\newlabel{ssub:pheytoin}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Carbamazepin}{128}}
\newlabel{ssub:carbamazepin}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Lamotrigin}{128}}
\newlabel{ssub:lamotrigin}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Valproins\IeC {\"a}ure}{128}}
\newlabel{ssub:valproins_ure}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Ethosuximid}{128}}
\newlabel{ssub:ethosuximid}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Gabapentin}{129}}
\newlabel{ssub:gabapentin}{{21.3.3}{129}}
\@writefile{toc}{\contentsline {subsubsection}{Levetiracetam}{129}}
\newlabel{ssub:levetiracetam}{{21.3.3}{129}}
\@writefile{toc}{\contentsline {subsubsection}{Benzodiazepine}{129}}
\newlabel{ssub:benzodiazepine}{{21.3.3}{129}}
\@writefile{toc}{\contentsline {subsubsection}{Phenobarbital, Primidon}{129}}
\newlabel{ssub:phenobarbital_primidon}{{21.3.3}{129}}
\@writefile{toc}{\contentsline {subsubsection}{Vigabatrin}{129}}
\newlabel{ssub:vigabatrin}{{21.3.3}{129}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.4}Antiepileptika - Indikationen}{129}}
\newlabel{sub:antiepileptika_indikationen}{{21.3.4}{129}}
\@writefile{toc}{\contentsline {section}{\numberline {21.4}Pharmakotherapie bei Status epilepticus}{129}}
\newlabel{sec:pharmakotherapie_bei_status_epilepticus}{{21.4}{129}}
\@writefile{toc}{\contentsline {subsubsection}{Diazepam}{129}}
\newlabel{ssub:diazepam}{{21.4}{129}}
\@writefile{toc}{\contentsline {subsubsection}{Phenytoin}{129}}
\newlabel{ssub:phenytoin}{{21.4}{129}}
\@writefile{toc}{\contentsline {chapter}{\numberline {22}Antidepressiva}{130}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antidepressiva}{{22}{130}}
\@writefile{toc}{\contentsline {section}{\numberline {22.1}Pharmakodynamik}{130}}
\newlabel{sec:pharmakodynamik}{{22.1}{130}}
\@writefile{toc}{\contentsline {paragraph}{Nicht-Selektive Monoamin-R\IeC {\"u}ckaufnahme-Hemmer (NSMRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{Selektive Serotonin/Noradrenalin-R\IeC {\"u}ckaufnahme-Hemmer (SSNRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{Selektive Serotonin-R\IeC {\"u}ckaufnahme-Hemmer (SSRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{Selektive Noradrenalin-R\IeC {\"u}ckaufnahme-Hemmer (SNRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{$\alpha _2$-Adrenozeptor-Antagonisten}{130}}
\@writefile{toc}{\contentsline {paragraph}{Monoamin-Oxidase-Hemmer (MAO-Hemmer)}{131}}
\@writefile{toc}{\contentsline {section}{\numberline {22.2}Nicht-selektive Monoamin-\IeC {\quotedblbase }Reuptake\IeC {\textquotedblleft }-Inhibitoren (NSMRI)}{131}}
\newlabel{sec:nicht_selektive_monoamin_reuptake_inhibitoren_nsmri_}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{131}}
\newlabel{ssub:pharmakokinetik}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{131}}
\newlabel{ssub:subsubsection_name}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{131}}
\newlabel{ssub:interaktionen}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{131}}
\newlabel{ssub:akute_vergiftung}{{22.2}{131}}
\@writefile{toc}{\contentsline {section}{\numberline {22.3}Selektive Serotonin-\IeC {\quotedblbase }Reuptake\IeC {\textquotedblleft }-Inhibitoren (SSRI)}{131}}
\newlabel{sec:selektive_serotonin_reuptake_inhibitoren_ssri_}{{22.3}{131}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{132}}
\newlabel{ssub:pharmakokinetik}{{22.3}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{132}}
\newlabel{ssub:unerw_nschte_wirkungen}{{22.3}{132}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{132}}
\newlabel{sub:akute_vergiftung}{{22.3}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{132}}
\newlabel{ssub:wechselwirkungen}{{22.3}{132}}
\@writefile{toc}{\contentsline {section}{\numberline {22.4}MAO-A-Hemer}{132}}
\newlabel{sec:mao_a_hemer}{{22.4}{132}}
\@writefile{toc}{\contentsline {section}{\numberline {22.5}Pharmaka zur Phasenprophylaxe affektiver Psychosen bzw. Therapie einer Manie}{132}}
\newlabel{sec:pharmaka_zur_phasenprophylaxe_affektiver_psychosen_bzw_therapie_einer_manie}{{22.5}{132}}
\@writefile{toc}{\contentsline {subsection}{\numberline {22.5.1}Lithium}{132}}
\newlabel{sub:lithium}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{132}}
\newlabel{ssub:einsatz}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{132}}
\newlabel{ssub:wirkmechanismus}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{132}}
\newlabel{ssub:pharmakokinetik}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{133}}
\newlabel{ssub:unerw_nschte_wirkungen}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{133}}
\newlabel{ssub:akute_vergiftung}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{Problem}{133}}
\newlabel{ssub:problem}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{133}}
\newlabel{ssub:wechselwirkungen}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{133}}
\newlabel{ssub:kontraindikationen}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {chapter}{\numberline {23}Neuroleptika}{134}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:neuroleptika}{{23}{134}}
\@writefile{toc}{\contentsline {section}{\numberline {23.1}"Klassiche" Neuroleptika}{134}}
\newlabel{sec:}{{23.1}{134}}
\@writefile{toc}{\contentsline {section}{\numberline {23.2}Wirkmechanismen / Nebenwirkungen klassischer Neuroleptika}{134}}
\newlabel{sec:wirkmechanismen_nebenwirkungen_klassischer_neuroleptika}{{23.2}{134}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{135}}
\newlabel{ssub:pharmakokinetik}{{23.2}{135}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{135}}
\newlabel{ssub:wechselwirkungen}{{23.2}{135}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{135}}
\newlabel{ssub:indikationen}{{23.2}{135}}
\@writefile{toc}{\contentsline {subsubsection}{Neuroleptikavergiftung}{136}}
\newlabel{ssub:neuroleptikavergiftung}{{23.2}{136}}
\@writefile{toc}{\contentsline {section}{\numberline {23.3}"Atypische" Neuroleptika}{136}}
\newlabel{sec:section_name}{{23.3}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.1}Neuroleptika mit anderem Wirkprofil}{136}}
\newlabel{sub:neuroleptika_mit_anderem_wirkprofil}{{23.3.1}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.2}Antagonismus am Serotonien 5-HT$_{2A}$ Rezeptor}{136}}
\newlabel{sub:antagonismus_am_serotonien_5_ht__}{{23.3.2}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.3}Nebenwirkungen}{136}}
\newlabel{sub:nebenwirkungen}{{23.3.3}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.4}Rezeptorprofil atyptischer Neuroleptika (Antagonismus)}{136}}
\newlabel{sub:rezeptorprofil_atyptischer_neuroleptika_}{{23.3.4}{136}}
\@writefile{toc}{\contentsline {chapter}{\numberline {24}Magen-Darm-Pharmaka}{137}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:magen_darm_pharmaka}{{24}{137}}
\@writefile{toc}{\contentsline {section}{\numberline {24.1}Regulation der Magensaftsekretion}{137}}
\newlabel{sec:regulation_der_magensaftsekretion}{{24.1}{137}}
\@writefile{toc}{\contentsline {subsubsection}{Kephale Phase}{137}}
\newlabel{sub:kephale_phase}{{24.1}{137}}
\@writefile{toc}{\contentsline {subsubsection}{Gastrale Phase}{137}}
\newlabel{ssub:gastrale_phase}{{24.1}{137}}
\@writefile{toc}{\contentsline {subsubsection}{Intestinale Phase}{137}}
\newlabel{ssub:intestinale_phase}{{24.1}{137}}
\@writefile{toc}{\contentsline {subsection}{\numberline {24.1.1}Regulation der H$^+$-Produktion im Magen}{137}}
\newlabel{sub:regulation_der_}{{24.1.1}{137}}
\@writefile{toc}{\contentsline {section}{\numberline {24.2}Antazida}{137}}
\newlabel{sec:antiazida}{{24.2}{137}}
\newlabel{ssub:unerw_nschte_wirkungen}{{24.2}{137}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{137}}
\@writefile{toc}{\contentsline {subsection}{\numberline {24.2.1}Schichtgitter Antazida}{137}}
\newlabel{sub:schichtgitter_antazida}{{24.2.1}{137}}
\newlabel{par:einsatz}{{24.2.1}{137}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{137}}
\@writefile{toc}{\contentsline {section}{\numberline {24.3}Protonenpumpenhemmer}{137}}
\newlabel{sec:protonenpumpenhemmer}{{24.3}{137}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{138}}
\newlabel{ssub:pharmakokinetik}{{24.3}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{138}}
\newlabel{ssub:unerw_nschte_wirkungen}{{24.3}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{138}}
\newlabel{ssub:interaktionen}{{24.3}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{138}}
\newlabel{ssub:einsatz}{{24.3}{138}}
\@writefile{toc}{\contentsline {section}{\numberline {24.4}H$_2$-Rezeptoragonisten}{138}}
\newlabel{sec:h__2_rezeptoragonisten}{{24.4}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{138}}
\newlabel{ssub:wirkmechanismus}{{24.4}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{138}}
\newlabel{ssub:pharmakokinetik}{{24.4}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkung}{138}}
\newlabel{ssub:unerw_nschte_wirkung}{{24.4}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{138}}
\newlabel{ssub:interaktionen}{{24.4}{138}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{138}}
\newlabel{ssub:einsatz}{{24.4}{138}}
\@writefile{toc}{\contentsline {section}{\numberline {24.5}Eradikationsbehandlung bei Helicobacter pylori-assoziierten Ulzera}{139}}
\newlabel{sec:eradikationsbehandlung_bei_helicobacter_pylori_assoziierten_ulzera}{{24.5}{139}}
\@writefile{toc}{\contentsline {section}{\numberline {24.6}Erbrechen}{139}}
\newlabel{sec:erbrechen}{{24.6}{139}}
\@writefile{toc}{\contentsline {subsubsection}{Ausl\IeC {\"o}sung des Brechreflexes}{139}}
\newlabel{ssub:ausl_sung_des_brechreflexes}{{24.6}{139}}
\@writefile{toc}{\contentsline {subsection}{\numberline {24.6.1}Emetika}{139}}
\newlabel{sub:emetika}{{24.6.1}{139}}
\@writefile{toc}{\contentsline {subsubsection}{Emetin}{139}}
\newlabel{ssub:emetin}{{24.6.1}{139}}
\@writefile{toc}{\contentsline {subsubsection}{Apomorphin}{139}}
\newlabel{ssub:apomorphin}{{24.6.1}{139}}
\@writefile{toc}{\contentsline {subsubsection}{Antiemetika}{139}}
\newlabel{ssub:antiemetika}{{24.6.1}{139}}
\newlabel{par:dopamin_d__2_rezeptor_antagonisten}{{24.6.1}{139}}
\@writefile{toc}{\contentsline {paragraph}{Dopamin D$_2$-Rezeptor-Antagonisten}{139}}
\newlabel{par:histamin_h__1_rezeptor_antagonisten}{{24.6.1}{139}}
\@writefile{toc}{\contentsline {paragraph}{Histamin H$_1$-Rezeptor-Antagonisten}{139}}
\newlabel{par:muscarin_rezeptor_antagonisten}{{24.6.1}{139}}
\@writefile{toc}{\contentsline {paragraph}{Muscarin-Rezeptor-Antagonisten}{139}}
\newlabel{par:serotonin_5_ht__3_rezeptor_antagonisten}{{24.6.1}{139}}
\@writefile{toc}{\contentsline {paragraph}{Serotonin-(5-HT$_3$)-Rezeptor-Antagonisten}{139}}
\newlabel{par:substanz_p_nk__1_rezeptor_antagonisten_}{{24.6.1}{140}}
\@writefile{toc}{\contentsline {paragraph}{Substanz-P-(NK$_1$)-Rezeptor-Antagonisten }{140}}
\newlabel{par:cannaboide}{{24.6.1}{140}}
\@writefile{toc}{\contentsline {paragraph}{Cannaboide}{140}}
\@writefile{toc}{\contentsline {section}{\numberline {24.7}Prokinetika}{140}}
\newlabel{sec:prokinetika}{{24.7}{140}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{140}}
\newlabel{ssub:wirkmechanismus}{{24.7}{140}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{140}}
\newlabel{ssub:pharmakokinetik}{{24.7}{140}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{140}}
\newlabel{ssub:unerw_nschte_wirkungen}{{24.7}{140}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{140}}
\newlabel{ssub:einsatz}{{24.7}{140}}
\@writefile{toc}{\contentsline {section}{\numberline {24.8}Diarrhoe}{140}}
\newlabel{sec:diarrhoe}{{24.8}{140}}
\@writefile{toc}{\contentsline {subsection}{\numberline {24.8.1}Ursachen}{141}}
\newlabel{sub:ursachen}{{24.8.1}{141}}
\@writefile{toc}{\contentsline {subsection}{\numberline {24.8.2}Therapie}{141}}
\newlabel{sub:therapie}{{24.8.2}{141}}
\@writefile{toc}{\contentsline {subsubsection}{Fl\IeC {\"u}ssigkeits- und Elektrolytersatz}{141}}
\newlabel{ssub:fl_ssigkeits_und_elektrolytersatz}{{24.8.2}{141}}
\@writefile{toc}{\contentsline {subsubsection}{Opiate / Enkephalinase-Hemmer}{141}}
\newlabel{ssub:opiate_enkephalinase_hemmer}{{24.8.2}{141}}
\@writefile{toc}{\contentsline {subsubsection}{Antibiotika}{141}}
\newlabel{ssub:antibiotika}{{24.8.2}{141}}
\@writefile{toc}{\contentsline {section}{\numberline {24.9}Obstipation}{141}}
\newlabel{sec:obstipation}{{24.9}{141}}
\@writefile{toc}{\contentsline {subsection}{\numberline {24.9.1}Ursachen}{141}}
\newlabel{sub:ursachen}{{24.9.1}{141}}
\@writefile{toc}{\contentsline {subsubsection}{Strenge Indikationsstellung f\IeC {\"u}r Laxantien!}{141}}
\newlabel{ssub:strenge_indikationsstellung_f_r_laxantien_}{{24.9.1}{141}}
\@writefile{toc}{\contentsline {subsection}{\numberline {24.9.2}Therapie}{141}}
\newlabel{sub:therapie}{{24.9.2}{141}}
\@writefile{toc}{\contentsline {subsubsection}{Quell- und Ballaststoffe, Gleitmittel}{141}}
\newlabel{ssub:quell_und_ballaststoffe_gleitmittel}{{24.9.2}{141}}
\@writefile{toc}{\contentsline {subsubsection}{Osmotisch wirksame Laxantien}{141}}
\newlabel{ssub:osmotisch_wirksame_laxantien}{{24.9.2}{141}}
\@writefile{toc}{\contentsline {subsubsection}{Stimulierende Laxantien}{142}}
\newlabel{ssub:stimulierende_laxantien}{{24.9.2}{142}}
